microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft biotech bull  bear x etf  labu labd  direxion brzu daily msci brazil bull x shareschad daily csi  china a share bear x shareschau daily csi  china a share bull x sharesclaw daily homebuilders  supplies bear x sharescom direxion auspice broad commodity strategy etfcure daily healthcare bull x sharescweb daily csi china internet index bull x sharesdfen daily aerospace  defense bull x sharesdpk daily msci developed markets bear x sharesdpst daily regional banks bull x sharesdrip daily sp oil  gas exp  prod bear x sharesdrn daily msci real estate bull x sharesdrv daily msci real estate bear x sharesdull daily silver miners index bear x sharesdusl daily industrials bull x sharesdust daily gold miners index bear x sharesdxcbx direxion indexed cvt strategy funddxcix direxion indexed commodity strategy fund – instdxctx direxion indexed commodity strategy fund – adxelx monthly emerging markets bull x funddxhlx monthly china bull x funddxhyx monthly high yield bull x funddxklx monthly  year treasury bull x funddxksx monthly  year treasury bear x funddxltx monthly  year treasury bull x funddxmax direxion indexed managed futures strategy fund – adxmcx direxion indexed managed futures strategy fund – cdxmix direxion indexed managed futures strategy fund – instdxnlx monthly nasdaq bull x funddxnsx monthly nasdaq bear x funddxqlx monthly nasdaq bull x funddxrlx monthly small cap bull x funddxrsx monthly small cap bear x funddxscx direxion indexed commodity strategy fund – cdxslx monthly sp  bull x funddxssx monthly sp  bear x funddxstx monthly  year treasury bear x funddzk daily msci developed markets bull x sharesedc daily msci emerging markets bull x sharesedz daily msci emerging markets bear x shareserx daily energy bull x sharesery daily energy bear x shareseryy daily energy bear x shareseufl daily msci european financials bull x shareseufs daily msci european financials bear x shareseurl daily ftse europe bull x shareseuxl daily euro stoxx  bull x sharesfas daily financial bull x sharesfaz daily financial bear x sharesfazz daily financial bear x sharesgasl daily natural gas related bull x sharesgasx daily natural gas related bear x sharesgush daily sp oil  gas exp  prod bull x shareshakk daily cyber security  it bull x shareshcyax direxion hilton tactical income fund – a shareshcycx direxion hilton tactical income fund – c shareshcyix direxion hilton tactical income fund – institutionalhydd daily high yield bear x sharesibln direxion ibillionaire index etfindl daily msci india bull x sharesjdst daily junior gold miners index bull x sharesjdst daily junior gold miners index bear x sharesjpnl daily msci japan bull x sharesknow direxion all cap insider sentiment shareskoru daily msci south korea bull x shareslabd daily sp biotech bear x shareslabs daily sp biotech bear x shareslabu daily sp biotech bull x shareslbj daily latin america bull x sharesllsc daily small cap bull x sharesllsp daily sp  bull x sharesmelt daily gold miners index bear x sharesmexx daily msci mexico bull x sharesmidu daily mid cap bull x sharesmidz daily mid cap bear x sharesnail daily homebuilders  supplies bull x sharesnugt daily gold miners index bull x sharespemvx evolution managed fundsqqqe direxion nasdaq equal weighted index sharesretl daily retail bull x sharesrusl daily russia bull x sharesruss daily russia bear x sharessagg daily total bond market bear x sharesshny daily silver miners index bull x sharessick daily healthcare bear x sharessmll daily small cap bull x sharessoxl daily semiconductor bull x sharessoxs daily semiconductor bear x sharesspdn daily sp  bear x sharessplz daily consumer staples bear x sharesspuu daily sp  bull x sharesspxl daily sp  bull x sharesspxs daily sp  bear x sharestecl daily technology bull x sharestecs daily technology bear x sharestecz daily technology bear x sharestmf daily  year treasury bull x sharestmv daily  year treasury bear x sharestna daily small cap bull x sharestpor daily transportation bull x sharestybs daily  year treasury bear x sharestyd daily  year treasury bull x sharestyns daily  year treasury bear x sharestyo daily  year treasury bear x sharestza daily small cap bear x sharesutlz daily utilities bear x sharesutsl daily utilities bull x shareswdrw daily regional banks bear x sharesyang daily ftse china bear x sharesyinn daily ftse china bull x shareszmlp direxion zacks mlp high income index shares direxion daily sp biotech bull and bear x shares fund symbol labu daily target  intraday indicative value labuiv bloomberg index spsibitr cusip k isin usk expense ratio grossnet     inception date may   fund symbol labd daily target  intraday indicative value labdiv bloomberg index spsibitr cusip k isin usk expense ratio grossnet     inception date may   overview the direxion daily sp biotech bull and bear x shares seek daily investment results before fees and expenses of  or  of the inverse or opposite of the performance of the sp biotechnology select industry index there is no guarantee the funds will meet their stated investment objectives these leveraged etfs seek a return that is  or  of the return of their benchmark index for a single day the funds should not be expected to provide three times or negative three times the return of the benchmark’s cumulative return for periods greater than a day labu labd fact sheet etf guide labu prospectus labd prospectus premium discount daily holdings download labu daily holdings csv download labd daily holdings csv daily holdings labu     daily sp biotech bull x shares trade date     shares outstanding  stock ticker security description shares price market value — bank of new york cash reserve    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — goldman finl sq trsry inst     — goldman finl sq trsry inst     — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    xbi spdr sp biotech etf    labd     daily sp biotech bear x shares trade date     shares outstanding  stock ticker security description shares price market value — bank of new york cash reserve    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — goldman finl sq trsry inst     — goldman finl sq trsry inst     — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    strategy  benefits key benefits you know that trading is different than investing but the opportunity to take advantage of shortterm trends is only won if you get the direction right whether you’re a bull or a bear direxion is with you our leveraged etfs are powerful tools built to help you magnify your shortterm perspective with daily x leverage go where there’s opportunity with bull and bear funds for both sides of the trade and stay agile – with liquidity to trade through rapidly changing markets leveraged and inverse etfs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage they seek daily goals and should not be expected to track the underlying index over periods longer than one day they are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments target index the sp biotechnology select industry index spsibitr is provided by standard  poor’s and includes domestic companies from the biotechnology industry the index is designed to measure the performance of the biotechnology subindustry based on the global industry classification standards gics one cannot directly invest in an index index top ten holdings  clovis oncology inc  exelixis inc  kite pharma inc  alexion pharmaceuticals inc  celgene corp  alnylam pharmaceuticals inc  gilead sciences inc  sarepta therapeutics inc  bioverativ inc  exact sciences corp  index sector weightings  medicalbiomedicalgenetics  medicaldrugs  therapeutics  medicalgeneric drugs  diagnostic kits  medical products  diagnostic equipment  drug delivery systems  index data as of  source bloomberg index sector weightings and top holdings are subject to change tax reporting supplemental tax documents  – ordinary income from us government obligations labd pricing and performance pricing and performance nav and market price information as of july   line chart shows pricing trend over the last  days fund symbol labu net asset value nav  nav   change   change  market price closing  market   change   change  premium  discount   change from last day trading fund symbol labd net asset value nav  nav   change   change  market price closing  market   change   change  premium  discount   change from last day trading monthly quarterly as of june   as of june   labu daily sp biotech bull x shares m  m  ytd  y  since inception inception date expense ratio  gross  net  m  m  ytd  y  since inception inception date expense ratio  gross  net  nav          market close      nav          market close      spsibitr benchmark index        labd daily sp biotech bear x shares m  m  ytd  y  since inception inception date expense ratio  gross  net  m  m  ytd  y  since inception inception date expense ratio  gross  net  nav          market close      nav          market close      spsibitr benchmark index         the net expense ratio includes management fees other operating expenses and acquired fund fees and expenses if acquired fund fees and expenses were excluded the net expense ratio would be  the funds’ adviser rafferty asset management llc “rafferty” has entered into an operating expense limitation agreement with each fund under which rafferty has contractually agreed to cap all or a portion of its management fee andor reimburse each fund for other expenses through september   to the extent that the fund’s total annual fund operating expenses exceed  of the fund’s daily net assets other than the following taxes swap financing and related costs acquired fund fees and expenses dividends or interest on short positions other interest expenses brokerage commissions and extraordinary expenses if these expenses were included the expense ratio would be higher the performance data quoted represents past performance past performance does not guarantee future results the investment return and principal value of an investment will fluctuate an investor’s shares when redeemed may be worth more or less than their original cost current performance may be lower or higher than the performance quoted returns for performance under one year are cumulative not annualized for the most recent monthend performance please visit the funds website at direxioninvestmentscom shortterm performance in particular is not a good indication of the fund’s future performance and an investment should not be made based solely on returns because of ongoing market volatility fund performance may be subject to substantial shortterm changes for additional information see the fund’s prospectus distributions distributions labu daily sp biotech bull x shares there are no recent distributions available for this fund labd daily sp biotech bear x shares there are no recent distributions available for this fund related reading knowledge related education articles and insights etf market pricing etf market prices are the prices at which investors buy or sell shares of an etf in the secondary market while etfs are designed to trade in line with their intraday values during times of significant market volatility an etf’s market price may vary more widely from its intraday value etf liquidity – four rules to consider liquidity transparency realtime trading and relatively low management fees are the reason why etfs are becoming more and more popular learn about the four key characteristics that investors should better understand in order to trade them properly more articles like this biotechnology value trading fund os lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors biotechnology value trading fund os lp check out list of companies and businesses related to biotechnology value trading fund os lp find out biotechnology value trading fund os lp address and contact details view other people related to biotechnology value trading fund os lp  coworkers colleagues companions etc address po box  ugland house grand cayman ky cayman islands companies related to biotechnology value trading fund os lp cikcompany namepositioncompany addressxoma corp seventh st berkeley cti biopharma corp western avenue suite  seattle infinity pharmaceuticals inc memorial drive cambridge glycomimetics inc medical center drive rockville cascadian therapeutics inc fourth avenue suite  seattle xenon pharmaceuticals inc   gilmore way burnaby vg walpine immune sciences inc elliott ave west suite  seattle  biotechnology value trading fund os lp on the web persons related to biotechnology value trading fund os lp  xoma corpnamepositioncity capital gp llcnew york lpnew york lpnew yorkjames g andressjames g andressdirector lake forestjames g andressdirector berkeleybaker biotech capital gp llcnew yorkbaker bros advisors gp llcnew yorkbaker bros advisors llc new yorkbaker bros advisors llcdirector new yorkbaker bros advisors lpdirector new yorkbaker brothers life sciences capital gp llcnew yorkbaker brothers life sciences lpnew yorkfelix bakerfelix bakernew yorkjulian bakerjulian bakerdirector new yorkbiotechnology value fund ii lpbiotechnology value fund l pwilliam k bowes jrdirector william k bowes jrdirector menlo parkwilliam k bowes jrdirector menlo parkwilliam k bowes jrdirector berkeleywilliam k bowes jrdirector berkeleyj david boyle iivp finance and cfo berkeleyj david boyle iivp finance and cfo berkeleythomas m burnsvp finance  cfo berkeleybvf incilbvf partners l pilbvf partners os ltdgrand caymanjohn l castellopresident ceo and berkeleyjohn l castellopresident ceo and berkeleypeter b davispeter b davisvp finance  cfo berkeleyclarence l delliosr vp operations and coo steven b englechairman ceo  president berkeleycharles j fisher jrdirector berkeleypeter barton huttdirector irvinepeter barton huttdirector berkeleypeter barton huttdirector berkeleypeter barton huttthomas kleinchief commercial officer berkeleyarthur md kornbergdirector arthur md kornbergdirector berkeleyfred kurlandcfo  vp finance menlo parkfred kurlandcfo  vp finance berkeleyfred kurlandcfo  vp finance berkeleymark n lampertsan franciscojoseph m limberdirector watertownjoseph m limberdirector berkeleychristopher j margolinvp general counsel  secy berkeleychristopher j margolinvp general counsel  secy berkeleychristopher j margolinberkeleysteven c mendellsteven c mendelldirector berkeleyjames r nealceo berkeleykelvin neudirector berkeleymatthew d perrydirector san franciscopaul d rubinsr vp clinical dev  cmo lexingtonpaul d rubinvp clinical dev  cmo berkeleypaul d rubinsr vp clinical dev  cmo berkeleypatrick j md phd scannonexec vp  cso berkeleypatrick j md phd scannonexecutive vice president berkeleypatrick j md phd scannonexec vp  cso berkeleyness w denman vandirector ness w denman vandirector berkeleyness w denman vandirector berkeleyness w denman vandirector berkeleyjohn variandirector fremontjohn variandirector  interim ceo berkeleyjohn varianceo berkeleytimothy p walbertdirector waukegantimothy p walbertdirector berkeleytimothy p walbertdirector berkeleyjack l wyszomierskidirector kenilworthjack l wyszomierskidirector berkeleyjack l wyszomierskidirector new hopejack l wyszomierskidirector berkeleypatrick j zennerpatrick j zennerdirector bedminsterpatrick j zennerdirector berkeleypatrick j zennerdirector morristownpersons related to biotechnology value trading fund os lp  cti biopharma corpnamepositioncitysteve aselageevp global commercial ops seattlesteve aselageevp global commercial ops seattlesteve aselageevp global commercial ops seattlesteve aselageevp global comm operations seattlesteve aselageevp global commercial ops seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerdirector seattlejohn h bauerseattlehealthcare sa baxter owner glattpark opfikonbaxter international incdeerfieldsteven e bennerseattlesteven e bennerevp chief medical officer seattlejames a biancodirector james a biancopresident and ceo seattlejames a biancoceo seattlejames a biancoceo seattlejames a biancopresident and ceo seattlejames a biancochief executive officer seattlejames a biancoceo seattlejames a biancoceo seattlejames a biancoceo seattlejames a biancoceo seattlejames a biancoceo seattlejames a biancoceo seattlejames a biancopresident and ceo seattlejames a biancopresident and ceo seattlejames a biancoseattlejames a biancopresident and ceo seattlejames a biancopresident and ceo seattlejames a biancopresident and ceo seattlejames a biancopresident and ceo seattlejames a biancopresident and ceo seattlejames a biancopresident and ceo seattlejames a biancopresident and ceo seattlejames a biancochief executive officer seattlejames a biancopresident and ceo seattlejames a biancopresident and ceo seattlejames a biancoceo seattlelouis a biancoevp finance  administration seattlelouis a biancoevp finance  administration seattlelouis a biancoevp finance  administration seattlelouis a biancoevp finance  administration seattlelouis a biancoevp finance  administration seattlelouis a biancoevp finance  administration seattlelouis a biancoevp finance  administration seattlebiotechnology value fund ii lpbiotechnology value fund l pjack l bowmandirector lummi islandjade brownevp chief business officer seattlebvf incilbvf partners l pil owner bvf partners os ltdgrand caymanjames canfieldchief administrative officer seattlejames canfieldchief administrative officer seattleadam r craigsee remarks new yorkphilips craigseattleeramian danielseattledaniel g eramianevp corporate communications seattledaniel g eramianevp corporate communications seattledaniel g eramianevp corporate communications seattledaniel g eramianevp corporate communications seattlelaurent fischerdirector watertownjohn m fluke jrdirector seattlejohn m fluke jrdirector seattlejohn m fluke jrdirector seattletelling frederickseattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlevartan gregoriandirector seattlekaren ignagnidirector seattlesamuel d isalysinger jackseattlebianco jamesseattlebauer johnseattleedward f kenneyevp chief operating officer seattlemark n lampertsan franciscorichard leigh jrevp general counsel seattlemax linkmax linkdirector seattlemax linkdirector seattlemax linkdirector seattlemax linkdirector seattlebianco louisseattlerichard l lovedirector richard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l loveseattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlerichard l lovedirector seattlemundinger maryseattlemichael a metzgerdirector los angelesmary oneil mundingerdirector minnetonkamary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerseattlemary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerdirector new yorkmary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerdirector seattlemary oneil mundingerdirector seattlephillip m phd nudelmandirector bellevuephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattlephillip m phd nudelmandirector seattleorbimed advisors llc owner orbimed capital gp vi llcnew yorkdavid ross parkinsondirector redwood citymatthew d perrydirector san franciscocraig philipspresident seattlecraig philipspresident seattlecraig philips seattlecraig philips mercer islandcraig philips mercer islandcraig philips mercer islandnudelman phillipseattleerich platzerdirector seattlematthew plunkettevp chief business officer seattlelove richardseattlebruce j seeleyevp chief commercial officer bothelljack w singerevp chief scientific officer seattlejack w singerevp chief medical officer seattlejack w singerevp global medical affairs seattlejack w singerevp global medical affairs seattlejack w singerevp global medical affairs seattlejack w singerevp global medical affairs seattlesilvano spinellievp development seattlesilvano spinellievp development seattlesilvano spinellievp development seattlesilvano spinellievp development seattlescott stromattevp clinical dev  reg affair seattlescott stromattevp clinical dev  reg affair seattlescott stromattemp clinical dev  reg affair seattlescott stromattevp clinical dev  reg affair seattlescott stromattevp clinical dev  reg affair seattlescott stromattevp clinical dev  reg affair seattlescott stromattevpclinical dev  reg affair seattlefred tellingdirector seattlefred tellingdirector seattlefred tellingdirector seattlefred tellingdirector seattlefred tellingdirector seattlefred tellingdirector seattlereed vaughn tucksondirector minnetonkareed vaughn tucksondirector seattlereed vaughn tucksondirector seattlereed vaughn tucksondirector seattlereed vaughn tucksondirector seattlereed vaughn tucksondirector seattlereed vaughn tucksondirector seattlegregorian vartanseattlepersons related to biotechnology value trading fund os lp  infinity pharmaceuticals incnamepositioncityjulian adamspresident of rd cambridgeperkins adelenecambridgeevnin anthonycambridgemartin bablerdirector san carlosmartin bablerdirector cambridgealexander e barkaspalo altojose baselgadirector cambridgeco beaconst helier jersey channel islco beacon owner st helier jersey channel islco beacon owner jersey channel islandsjeffrey berkowitzdirector bernwilliam c bertrand jrgeneral counsel gaithersburgbiotechnology value fund ii lpbiotechnology value fund l plawrence e blochpresident san diegolawrence e blochevp cfo  cbo cambridgelawrence e blochevp cfo  cbo cambridgethomas joseph burkeassistant treasurer cambridgebvf incilbvf partners l pil owner bvf partners os ltdgrand caymantaylor crouchchief operating officer san diegotaylor crouchpresident  coo san diegod ronald danieldirector new yorkcolin dollerydirector san diegolander ericcambridgeanthony b evnindirector new yorkanthony b evnindirector cambridgeanthony b evnindirector new yorkgwen a fyfedirector sunnyvalegwen a fyfedirector cambridgegwen a fyfedirector cambridgefyfe gwencambridgejoshua hamermeshvp business  corporate dev cambridgedaniel harveyvice president san diegoharry f hixson jrdirector san diegoharry f hixson jrdirector cambridgesteven h holtzmandirector cambridgesmith iancambridgeadams juliancambridgesujay kangochief commercial officer bridgewatermichael kauffmandirector cambridgecraig kussmanchief financial officer san diegocraig kussmanchief financial officer san diegojeffery kutokchief scientific officer cambridgewinston kc lamgeneral counsel cambridgemark n lampertsan franciscoeric s landerdirector bostoneric s landerdirector cambridgeeric s landerdirector cambridgepatrick paktin leedirector london united kingdompatrick paktin leedirector cambridgearnold j levinedirector princetonarnold j levinedirector cambridgealan lewisdirector san diegojohn lilligchief technology officer san diegojohn lilligchief technology officer san diegochristopher m lindblomprincipal accounting officer cambridgechristopher m lindblomsee remarks cambridgedouglas a livingstonsvp chemistry san diegothomas j jr lynchdirector cambridgebabler martincambridgevenuti michaelcambridgefranklin mossdirector cambridgefranklin mossdirector cambridgerichard nealevice president san diegorichard nealevice president san diegoselby normancambridgevito j palombellachief scientific officer cambridgelee patrickcambridgesantabarbara pedrocambridgeadelene q perkinschief executive officer cambridgericcardo pigliuccichief executive officer san diegoriccardo pigliuccichairman  ceo san diegoprospect management co ii llcpalo altoprospect management co llcpalo altoprospect venture partners ii lppalo altoprospect venture partners lppalo altogerald e quirksee remarks cambridgeurs regenassvice president san diegours regenassvice president san diegorosebay medical co lp owner oklahoma cityherm rosenmandirector san diegoherm rosenmandirector cambridgedavid rothchief medical officer cambridgepedro santabarbarachief medical officer cambridgevicki l satodirector cambridgedavid schnellpalo altonorman c selbydirector lexingtonnorman c selbydirector cambridgenorman c selbydirector cambridgenorman c selbydirector cambridgeian f smithdirector cambridgeian f smithdirector cambridgeian f smithdirector cambridgeholtzman stevecambridgejames b tananbaumdirector palo altojames b tananbaumdirector cambridgeseth a taskergeneral counsel cambridgelynch thomascambridgejeffrey k tongvp cor  product development cambridgewinselow s jr tuckervice president marketing cambridgemichael c venutidirector san diegomichael c venutidirector cambridgepalombella vitocambridgejohn peter walkerdirector san diegopersons related to biotechnology value trading fund os lp  glycomimetics incnamepositioncitypatricia s andrewsdirector wilmingtonjohn j baldwindirector gaithersburgm james barrettdirector baltimorem james barrettdirector timoniumpeter j barris owner baltimorepeter j barris owner timoniumforest basketttimoniumbiotechnology value fund ii lpbiotechnology value fund l pbvf incilbvf partners l pilbvf partners os ltdgrand caymanryan d dranttimoniumtop franklingaithersburgmark alan goldbergdirector needhammark alan goldberggaithersburgwilliam m gustdirector gaithersburgbrian m hahncfo gaithersburgthackray helengaithersburgmichael a henosdirector michael a henosdirector gaithersburgbaldwin johngaithersburgmagnani johngaithersburgdaniel m juniusdirector patrick j kerinstimoniumrachel k kingpresident ceo gaithersburgscott koenigdirector rockvillekrishna kittu kolluritimoniummark n lampertsan franciscobarrett mgaithersburgjohn l magnanisvp of research cso gaithersburghenos michaelgaithersburgdavid m motttimoniumnea  gp ltdtimoniumnea partners  l pbaltimorenea partners  l ptimoniumpartners  limited partnership neatimoniumnew enterprise associates  l p owner baltimorenew enterprise associates  l p owner timoniumnew enterprise associates  lp owner timoniumtimothy r pearsondirector rockvilletimothy r pearsondirector gaithersburgking rachelgaithersburgscott d sandell owner baltimorescott d sandell owner timoniumsanofiparishelen m thackraysvp clinical development cmo gaithersburgfranklin h top jrdirector gaithersburgravi viswanathantimoniumharry r wellertimoniumgust williamgaithersburgpersons related to biotechnology value trading fund os lp  cascadian therapeutics incnamepositioncityacm capital partners llcsan franciscoayer capital management lp owner san franciscoayer capital partners llcsan franciscoayer capital partners llcsan franciscorobert azelbydirector seattlepeter j barrisbaltimorebiotechnology value fund ii lpbiotechnology value fund ii lpchicagobiotechnology value fund ii lpchicagobiotechnology value fund ii lpsan franciscobiotechnology value fund l pbiotechnology value fund l pchicagobiotechnology value fund l pchicagobiotechnology value fund l psan franciscos robert blairdirector bellevuestephen burleysan diegobvf incilbvf incilchicagobvf incilsan franciscobvf incilchicagobvf partners l pilbvf partners l pil owner chicagobvf partners l pil owner san franciscobvf partners l pilchicagobvf partners os ltdgrand caymangary christiansonchief operating officer bellevuegary christiansonchief operating officer seattlegary christiansonchief operating officer seattlehenney christopherseattlehenney christopherseattlespiegelman danielseattlespiegelman danielseattlehausman dianaseattlewilliams douglasseattlejulia marie eastlandcfo  vp corp dev seattlejulia marie eastlandcfo  vp corp development seattlejulia marie eastlandcfo  vp corp dev seattlegwen a fyfedirector sunnyvalechristianson garyseattlechristianson garyseattlegrowth equity opportunities iv llctimoniumdiana hausmanchief medical officer seattlediane hausmanseattlechristopher s henneydirector seattlechristopher s henneydirector seattlechristopher s henneydirector san diegochristopher s henneydirector seattleinvestment  llcchicagorichard l jacksondirector bellevuerichard l jacksondirector cincinnatirichard l jacksondirector seattlerichard l jacksondirector seattlesteven p jamesdirector venkatesan jayseattleeastland juliaseattleeastland juliaseattleshashi karanseattleshashi k karancorporate controller seattlerobert l kirkmanpresident  ceo seattlerobert l kirkmanpresidentceo bellevuerobert l kirkmanseattlerobert l kirkmanpresident  ceo seattlelynn kirkpatrickchief scientific officer tucsonmark n lampertdirector san franciscomark n lampertsan franciscomark n lampertsan franciscomark n lampertsan franciscoted w lovedirector sunnyvaleted w lovedirector seattlejoshua makowerdavid m mottgaithersburgscott dunseth myerspresident and ceo hackensacknea  gp llctimoniumnea partners  lptimoniumnew enterprise associates  lptimoniumscott robert petersonchief scientific officer seattlescott robert petersonchief scientific officer seattlejackson richardseattlejackson richardseattlekirkman robertseattlekirkman robertseattlejon sakodatimoniumscott d sandellbaltimorepeterson scottseattlekaran shashiseattlepeter w sonsinimenlo parkdaniel k spiegelmandirector palo altodaniel k spiegelmandirector seattledaniel k spiegelmandirector seattledaniel k spiegelmanpalo altodaniel k spiegelmandirector palo altodaniel k spiegelmandirector seattledaniel k spiegelmandirector seattlew vickery stoughtondirector bellevuew vickery stoughtondirector wellesley hillsw vickery stoughtondirector seattlew vickery stoughtondirector seattleedward a taylorcfo vp fin admin sec edmontonedward a taylorcfo vp fin  admin sec edmontonlove tedseattlejay venkatesansan franciscojay venkatesansan franciscojay venkatesansan franciscojay venkatesanevp and general manager seattlejay venkatesanevp and general manager seattleravi viswanathantimoniumstoughton wseattlestoughton wseattleluke nathaniel walkerseattlemichael c welshbellevuedouglas e williamsdirector seattledouglas e williamsdirector seattlepersons related to biotechnology value trading fund os lp  xenon pharmaceuticals incnamepositioncitymohammad azabdirector mohammad azabdirector burnabymohammad azabdirector burnabybiotechnology value fund ii lpbiotechnology value fund l pgary bridgerevp research  development burnabybvf incilbvf partners l pil owner bvf partners os ltdgrand caymancharles j cohenvp biology burnabykaren g corrainigen counsel  corp secretary burnabyjames r empfieldsvp drug discovery burnabyjohnston l evansdirector new yorkjohnston l evansdirector burnabysteven gannondirector burnabyy paul goldbergsvp clinical development burnabydawn grahamdirector san franciscomichael r haydendirector burnabymichael r haydendirector burnabyfrank a hollerdirector burnabymark n lampertsan franciscoian mortimercfo  coo burnabyassociates llp mx owner cincinnatigary patoudirector walthamgary patoudirector burnabygary patoudirector burnabysimon n pimstonepresident  ceo burnabysherrington robinsvp bus  corp development burnabyrichard h schellerdirector evan a steindirector burnabymichael m tarnowdirector rockvillemichael m tarnowdirector burnabymichael m tarnowdirector burnabyraymond winquisthead translational research burnabypersons related to biotechnology value trading fund os lp  alpine immune sciences incnamepositioncityalpine bioventures gp llcseattlealpine immunosciences lpseattlebiotechnology value fund ii lpbiotechnology value fund l pbvf incilbvf partners l pil owner bvf partners os ltdgrand caymanr michael carruthersinterim president  cfo boulderjon congletonpresident and ceo boulderrobert conwaydirector boulderdeerfield capital lp et alnew yorkmanagement co ny deerfielddeerfield private desigan fund l pnew yorkdeerfield private design fund ii lpnew yorkdeerfield private design international ii lproad town tortoladeerfield private design international ii ltdnew yorkdeerfield private design international lpnew yorkdeerfield special situations fund lpnew yorkof arnold h snider estate iii owner boulderloh evanboulderjames e flynndirector new yorkhoward p furstdirector south san franciscosherif gabrielvice president research bouldermitchell goldexecutive chairman and ceo hadley harbor master investors cayman lp owner bostonhawkes bay master investors cayman lp owner bostonfurst howardbouldersamuel d isalyjennison global healthcare master fund ltd owner new yorkmoore johnboulderleff jonathanboulderloscalzo josephbouldermark n lampertsan franciscojonathan s leffdirector brisbaneevan lohdirector bostonjohn r mooredirector boulderorbimed advisors llcdirector orbimed capital gp vi llcnew yorkstanford l pengsee remarks seattlejames paul rickeysenior vp and cfo seattlerock springs capital management lp owner baltimoredavid malcom rodmanexec vice president and cmo boulderpaul j sekhridirector cambridgesteven shoemakervp clinical rd bouldercynthia smithcoppellpeter a thompsondirector bellevuetiger management llcnew yorktiger partners gp llcnew yorktiger partners lpnew yorksokolowski tomboulderjames n topperdirector seattlejanice trohaexec vice president  coo boulderjay venkatesanpresident cambridge insider trading  biotechnology value trading fund os lp  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  biotechnology value trading fund os lp select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  am cti biopharma corp ctic bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    directindirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   indirect view   secformcom all rights reserved archives        wed  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  insider trading  biotechnology value fund l p  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  biotechnology value fund l p select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  am cti biopharma corp ctic bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    directindirect view sale  pm chemocentryx inc ccxi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark nbvf investments llcother    indirect view sale  pm chemocentryx inc ccxi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark nbvf investments llc owner    indirect view sale  pm chemocentryx inc ccxi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark nbvf investments llc owner    indirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   indirect view other  pm nana chemocentryx inc ccxi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark nbvf investments llcother   indirect view other  pm nana oncothyreon inc onty bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark n owner   indirect view other  pm nana oncothyreon inc onty bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark n owner   indirect view other  pm na oncothyreon inc onty bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark n owner   indirect view other  pm na oncothyreon inc onty bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark n owner   indirect view   secformcom all rights reserved archives        wed  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  insider trading  biotechnology value fund l p  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  biotechnology value fund l p select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  pm infinity pharmaceuticals inc infi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    direct view purchase  am cti biopharma corp ctic bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf inclampert mark n owner    directindirect view sale  pm chemocentryx inc ccxi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark nbvf investments llcother    indirect view sale  pm chemocentryx inc ccxi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark nbvf investments llc owner    indirect view sale  pm chemocentryx inc ccxi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark nbvf investments llc owner    indirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   direct view option award  pm nana cascadian therapeutics inc onty lampert mark nbvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbiotechnology value trading fund os lpbvf partners os ltdbvf incdirector owner   indirect view other  pm nana chemocentryx inc ccxi bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark nbvf investments llcother   indirect view other  pm nana oncothyreon inc onty bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark n owner   indirect view other  pm nana oncothyreon inc onty bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark n owner   indirect view other  pm na oncothyreon inc onty bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark n owner   indirect view other  pm na oncothyreon inc onty bvf partners l pbiotechnology value fund l pbiotechnology value fund ii lpbvf inclampert mark n owner   indirect view   secformcom all rights reserved archives        wed  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  biotech invest n v bizpediaxyz  we monitor changes in companies bizpediaxyz  we monitor changes in companies biotech invest n v free email watchdog get free email notifications about news in biotech invest n v the service is free and you can unsubscribe at any time general  filings  cik number  biotech invest n v addresssnipweg curacaowillemstad  earliest known filing february  latest known filing may  company filings sec filings are a great source of information for companies including investments company events and all sorts of other information biotech invest n v has  filings view biotech invest n v filings similar companiesbiotechnica international inc biotechnology investments ltd biotechnology venture fund satetraven fund sa biotechnology value fund l p biotechnology investment group l l c et al biotech holdings ltd biotechnology development fund lp biotech holdrs trust biotech international ltd biotechnology value fund ii lp biotech horizons fund lp biotech boxes biotech insight fund lp biotech capital partners lp biotechnology development fund iv lp biotechnology development fund ii lp biotech focus n v biotech growth n v biotech target n v biotech horizons offshore fund ltd biotechonomy sg fund i lp biotechonomy sg entrepreneur fund i lp biotech knowledge llc biotech fonds vlaanderen nv biotech medics inc biotechnology development fund iv affiliates lp biotech products services  research inc biotech development group llc biotech long short fund lp biotechnology value trading fund os lp bizpediaxyz collect news financial information sec filings stock information contact information personal information information about investments etc about biotech invest n v biotechnology value fund l p sc g filing concerning ctmx on  whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active schedule g filed by biotechnology value fund l p total shares  subject company cytomx therapeut  view complete ownership history backtest filed as of date  event date  overall  ownership  reporting persons name solevoting power sharedvoting power soledispositive power shareddispositive power aggregateamount owned percentof class biotechnology value fund lp       biotechnology value fund ii lp       biotechnology value trading fund os lp       bvf partners os ltd       bvf partners lp       bvf inc       mark n lampert       view original filing on edgars raw filing contents txt   hdrsgml    accession number  conformed submission type sc g public document count  filed as of date  date as of change  subject company company data company conformed name cytomx therapeutics inc central index key  standard industrial classification pharmaceutical preparations  irs number  fiscal year end  filing values form type sc g sec act  act sec file number  film number  business address street   oyster point blvd street  suite  city south san francisco state ca zip  business phone  mail address street   oyster point blvd street  suite  city south san francisco state ca zip  filed by company data company conformed name biotechnology value fund l p central index key  standard industrial classification investment advice  irs number  state of incorporation de fiscal year end  filing values form type sc g business address street   sansome st street  th fl city san francisco state ca zip  business phone  mail address street   sansome st street  th fl city san francisco state ca zip  sc g  scgcythtm schedule g  united states securities and exchange commission washington dc  schedule g rule d information to be included in statements filed pursuant to rules db c and d and amendments thereto filed pursuant to rule db amendment no      cytomx therapeutics inc  name of issuer common stock  par value  title of class of securities f    cusip number june    date of event which requires filing of this statement   check the appropriate box to designate the rule pursuant to which this schedule is filed    ☐  rule db    ☒  rule dc    ☐  rule dd                     the remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page the information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section  of the securities exchange act of  “act” or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes   cusip no f          name of reporting person                     biotechnology value fund lp        check the appropriate box if a member of a group a ☒         b ☐                  sec use only                                    citizenship or place of organization                     delaware   number of      sole voting power   shares           beneficially          shares   owned by      shared voting power   each           reporting            person with      sole dispositive power                        shares          shared dispositive power                                 aggregate amount beneficially owned by each reporting person                             check box if the aggregate amount in row  excludes certain shares     ☐                          percent of class represented by amount in row                              type of reporting person                     pn       cusip no f        name of reporting person                     biotechnology value fund ii lp        check the appropriate box if a member of a group a ☒         b ☐                  sec use only                                    citizenship or place of organization                     delaware   number of      sole voting power   shares           beneficially          shares   owned by      shared voting power   each           reporting            person with      sole dispositive power                        shares          shared dispositive power                                 aggregate amount beneficially owned by each reporting person                             check box if the aggregate amount in row  excludes certain shares     ☐                          percent of class represented by amount in row                              type of reporting person                     pn       cusip no f          name of reporting person                     biotechnology value trading fund os lp        check the appropriate box if a member of a group a ☒         b ☐                  sec use only                                    citizenship or place of organization                     cayman islands   number of      sole voting power   shares           beneficially          shares   owned by      shared voting power   each           reporting            person with      sole dispositive power                        shares          shared dispositive power                                 aggregate amount beneficially owned by each reporting person                             check box if the aggregate amount in row  excludes certain shares     ☐                          percent of class represented by amount in row                      less than         type of reporting person                     pn       cusip no f          name of reporting person                     bvf partners os ltd        check the appropriate box if a member of a group a ☒         b ☐                  sec use only                                    citizenship or place of organization                     cayman islands   number of      sole voting power   shares           beneficially          shares   owned by      shared voting power   each           reporting            person with      sole dispositive power                        shares          shared dispositive power                                 aggregate amount beneficially owned by each reporting person                             check box if the aggregate amount in row  excludes certain shares     ☐                          percent of class represented by amount in row                      less than         type of reporting person                     co       cusip no f          name of reporting person                     bvf partners lp        check the appropriate box if a member of a group a ☒         b ☐                  sec use only                                    citizenship or place of organization                     delaware   number of      sole voting power   shares           beneficially          shares   owned by      shared voting power   each           reporting            person with      sole dispositive power                        shares          shared dispositive power                                 aggregate amount beneficially owned by each reporting person                             check box if the aggregate amount in row  excludes certain shares     ☐                          percent of class represented by amount in row                              type of reporting person                     pn ia       cusip no f          name of reporting person                     bvf inc        check the appropriate box if a member of a group a ☒         b ☐                  sec use only                                    citizenship or place of organization                     delaware   number of      sole voting power   shares           beneficially          shares   owned by      shared voting power   each           reporting            person with      sole dispositive power                        shares          shared dispositive power                                 aggregate amount beneficially owned by each reporting person                             check box if the aggregate amount in row  excludes certain shares     ☐                          percent of class represented by amount in row                              type of reporting person                     co       cusip no f          name of reporting person                     mark n lampert        check the appropriate box if a member of a group a ☒         b ☐                  sec use only                                    citizenship or place of organization                     united states   number of      sole voting power   shares           beneficially          shares   owned by      shared voting power   each           reporting            person with      sole dispositive power                        shares          shared dispositive power                                 aggregate amount beneficially owned by each reporting person                             check box if the aggregate amount in row  excludes certain shares     ☐                          percent of class represented by amount in row                              type of reporting person                     in       cusip no f     item aname of issuer   cytomx therapeutics inc a delaware corporation the “issuer”   item baddress of issuers principal executive offices    oyster point boulevard suite  south san francisco california    item aname of person filing item baddress of principal business office or if none residence item ccitizenship   biotechnology value fund lp “bvf”  sansome street th floor san francisco california  citizenship delaware   biotechnology value fund ii lp “bvf”  sansome street th floor san francisco california  citizenship delaware   biotechnology value trading fund os lp “trading fund os” po box  ugland house grand cayman ky cayman islands citizenship cayman islands   bvf partners os ltd “partners os” po box  ugland house grand cayman ky cayman islands citizenship cayman islands   bvf partners lp “partners”  sansome street th floor san francisco california  citizenship delaware   bvf inc  sansome street th floor san francisco california  citizenship delaware   mark n lampert “mr lampert”  sansome street th floor san francisco california  citizenship united states   each of the foregoing is referred to as a “reporting person” and collectively as the “reporting persons”  cusip no f     item dtitle of class of securities   common stock par value  per share the “common stock”   item ecusip number   f     item if this statement is filed pursuant to rule db or db or c check whether the person filing is a   x not applicable       a   broker or dealer registered under section  of the exchange act       b   bank as defined in section a of the exchange act       c   insurance company as defined in section a of the exchange act       d   investment company registered under section  of the investment company act       e   an investment adviser in accordance with rule dbiie       f   an employee benefit plan or endowment fund in accordance with rule dbiif       g   a parent holding company or control person in accordance with rule dbiig       h   a savings association as defined in section b of the federal deposit insurance act       i   a church plan that is excluded from the definition of an investment company under section c of the investment company act       j   group in accordance with rule dbiij         k   group in accordance with rule dbiik if filing as a nonus institution in accordance with rule dbiij please specify the type of institution    item ownership   aamount beneficially owned   as of the close of business on june   i bvf beneficially owned  common stock ii bvf beneficially owned  common stock and iii trading fund os beneficially owned  common stock   partners os as the general partner of trading fund os may be deemed to beneficially own the  common stock beneficially owned by trading fund os   partners as the general partner of bvf bvf the investment manager of trading fund os and the sole member of partners os may be deemed to beneficially own the  common stock beneficially owned in the aggregate by bvf bvf trading fund os and a certain partners managed accounts the “partners managed accounts” including  common stock held in the partners managed accounts  cusip no f     bvf inc as the general partner of partners may be deemed to beneficially own the  common stock beneficially owned by partners   mr lampert as a director and officer of bvf inc may be deemed to beneficially own the  common stock beneficially owned by bvf inc   the foregoing should not be construed in and of itself as an admission by any reporting person as to beneficial ownership of any common stock owned by another reporting person partners os disclaims beneficial ownership of the common stock beneficially owned by trading fund os each of partners bvf inc and mr lampert disclaims beneficial ownership of the common stock beneficially owned by bvf bvf trading fund os and the partners managed accounts and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities   bpercent of class   the following percentages are based on  shares of common stock outstanding as of april   which is the total number of shares of common stock outstanding as reported in the issuer’s definitive proxy statement filed with the securities and exchange commission on may     as of the close of business on june   i bvf beneficially owned approximately  of the outstanding common stock ii bvf beneficially owned approximately  of the outstanding common stock iii trading fund os beneficially owned less than  of the outstanding common stock iv partners os may be deemed to beneficially own less than  of the outstanding common stock and v each of partners bvf inc and mr lampert may be deemed to beneficially own approximately  of the outstanding common stock less than  of which is held in the partners managed accounts   cnumber of shares as to which such person has   isole power to vote or to direct the vote   see cover pages items    iishared power to vote or to direct the vote   see cover pages items    iiisole power to dispose or to direct the disposition of   see cover pages items    ivshared power to dispose or to direct the disposition of   see cover pages items   cusip no f     item ownership of five percent or less of a class   not applicable   item ownership of more than five percent on behalf of another person   partners bvf inc and mr lampert share voting and dispositive power over the shares of common stock beneficially owned by bvf bvf trading fund os and the partners managed accounts   item identification and classification of the subsidiary that acquired the security being reported on by the parent holding company or control person   not applicable   item identification and classification of members of the group   see exhibit    item notice of dissolution of group   not applicable   item certifications   by signing below each of the undersigned certifies that to the best of its knowledge and belief the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect    cusip no f   signature   after reasonable inquiry and to the best of his knowledge and belief each of the undersigned certifies that the information set forth in this statement is true complete and correct   dated june     biotechnology value fund lp   bvf inc         by bvf partners lp its general partner   by s mark n lampert by bvf inc its general partner     mark n lampert         president by s mark n lampert         mark n lampert         president   s mark n lampert       mark n lampert         biotechnology value fund ii lp                   by bvf partners lp its general partner         by bvf inc its general partner                     by s mark n lampert         mark n lampert           president                                 bvf partners lp                     by bvf inc its general partner                     by s mark n lampert           mark n lampert           president                                 bvf partners os ltd             by bvf partners lp its sole member     by bvf inc its general partner             by s mark n lampert       mark n lampert       president                     biotechnology value trading fund os lp             by bvf partners lp its investment manager     by bvf inc its general partner             by s mark n lampert       mark n lampert       president        ex  extogcythtm joint filing agreement exhibit    joint filing agreement   the undersigned hereby agree that the statement on schedule g dated june   with respect to the shares of common stock of cytomx therapeutics inc and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of rule dk under the securities exchange act of  as amended   dated june     biotechnology value fund lp   bvf inc         by bvf partners lp its general partner   by s mark n lampert by bvf inc its general partner     mark n lampert         president by s mark n lampert         mark n lampert         president   s mark n lampert       mark n lampert         biotechnology value fund ii lp                   by bvf partners lp its general partner         by bvf inc its general partner                     by s mark n lampert         mark n lampert           president                                 bvf partners lp                     by bvf inc its general partner                     by s mark n lampert           mark n lampert           president                                 bvf partners os ltd             by bvf partners lp its sole member     by bvf inc its general partner             by s mark n lampert       mark n lampert       president                     biotechnology value trading fund os lp             by bvf partners lp its investment manager     by bvf inc its general partner             by s mark n lampert       mark n lampert       president           elevate your investments try it for free biotechnology value fund l p g filing  insider monkey companies  see all hedge funds  see all insiders  see all institutional investors  see all click here to see all results for sorry no results has been found matching your query adblocker detected dear valued visitor we have noticed that you are using an ad blocker software although advertisements on the web pages may degrade your experience our business certainly depends on them and we can only keep providing you highquality research based articles as long as we can display ads on our pages to view this article you can disable your ad blocker and refresh this page or simply login we only allow registered users to use ad blockers you can sign up for free by clicking here or you can login if you are already a member home  insider trading  latest d and g filings  g filing  filing details accession number  form type g filing publication date   filed by biotechnology value fund l p company anthera pharmaceuticals inc nasdaqanth filing date  sec url g filing ownership summary please notice the below summary table is generated without human intervention and may contain errors please refer to the complete filing displayed below for exact figures name sole voting power shared voting power sole dispositive power shared dispositive power aggregate amount owned power percent of class biotechnology value trading fund os       bvf partners os ltd       bvf partners       bvf inc       mark n lampert       filing united states securities and exchange commission washington dc  schedule g rule d information to be included in statements filed pursuant to rules db c and d and amendments thereto filed pursuant to rule db   amendment no      anthera pharmaceuticals inc  name of issuer   common stock  par value  title of class of securities   u    cusip number   september    date of event which requires filing of this statement     check the appropriate box to designate the rule pursuant to which this schedule is filed      o  rule db      x  rule dc      o  rule dd        the remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page         the information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of section  of the securities exchange act of  “act” or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes           consists of  of series x preferred stock defined in item  convertible into approximately  shares of common stock assuming a series x conversion price defined in item  of  as of the date hereof the series x preferred stock conversion limitation described in the next sentence limits the aggregate conversion of series x preferred stock by the reporting persons the series x preferred stock may not be converted if after such conversion the reporting persons would beneficially own as determined in accordance with section d of the securities exchange act of  more than  of the number of shares of common stock then issued and outstanding in providing beneficial ownership described herein the reporting persons have assumed only certain series x preferred stock owned by bvf and bvf would be fully converted certain series x preferred stock held in the partners managed account would be partially converted and the remaining series x preferred stock owned by trading fund os would remain unconverted thereby bringing the reporting persons to the aggregate  limitation excludes an option to purchase  shares of series x preferred stock due to the beneficial ownership limitation defined in item  excludes warrants defined in item  to purchase shares of common stock due to the beneficial ownership limitation the reporting persons may choose to convert or exercise as applicable the series x preferred stock series x preferred option defined in item  series x preferred stock defined in item  or warrants in other amounts among the reporting persons while continuing to comply with the beneficial ownership limitation see item a for a full description of the reporting person’s beneficial ownership      name of reporting person   bvf partners os ltd  check the appropriate box if a member of a group   a x   b o  sec use only    citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with  sole voting power    shares  shared voting power      sole dispositive power    shares  shared dispositive power      aggregate amount beneficially owned by each reporting person      check box if the aggregate amount in row  excludes certain shares   ¨  percent of class represented by amount in row        type of reporting person   co     excludes  of series x preferred stock defined in item  convertible into approximately  shares of common stock assuming a series x conversion price defined in item  of  as of the date hereof the series x preferred stock conversion limitation described in the next sentence limits the aggregate conversion of series x preferred stock by the reporting persons the series x preferred stock may not be converted if after such conversion the reporting persons would beneficially own as determined in accordance with section d of the securities exchange act of  more than  of the number of shares of common stock then issued and outstanding in providing beneficial ownership described herein the reporting persons have assumed only certain series x preferred stock owned by bvf and bvf would be fully converted certain series x preferred stock held in the partners managed account would be partially converted and the remaining series x preferred stock owned by trading fund os would remain unconverted thereby bringing the reporting persons to the aggregate  limitation excludes an option to purchase  shares of series x preferred stock due to the beneficial ownership limitation defined in item  excludes warrants defined in item  to purchase shares of common stock due to the beneficial ownership limitation the reporting persons may choose to convert or exercise as applicable the series x preferred stock series x preferred option defined in item  series x preferred stock defined in item  or warrants in other amounts among the reporting persons while continuing to comply with the beneficial ownership limitation see item a for a full description of the reporting person’s beneficial ownership      name of reporting person   bvf partners lp  check the appropriate box if a member of a group   a x   b o  sec use only    citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with  sole voting power    shares  shared voting power      sole dispositive power    shares  shared dispositive power      aggregate amount beneficially owned by each reporting person      check box if the aggregate amount in row  excludes certain shares   ¨  percent of class represented by amount in row       type of reporting person   pn ia     consists of  series x preferred stock defined in item  convertible into approximately  shares of common stock assuming a series x conversion price defined in item  of  as of the date hereof the series x preferred stock conversion limitation described in the next sentence limits the aggregate conversion of series x preferred stock by the reporting persons the series x preferred stock may not be converted if after such conversion the reporting persons would beneficially own as determined in accordance with section d of the securities exchange act of  more than  of the number of shares of common stock then issued and outstanding in providing beneficial ownership described herein the reporting persons have assumed only certain series x preferred stock owned by bvf and bvf would be fully converted certain series x preferred stock held in the partners managed account would be partially converted and the remaining series x preferred stock owned by trading fund os would remain unconverted thereby bringing the reporting persons to the aggregate  limitation as such the reporting persons hold additional shares of series x preferred stock convertible into approximately  shares of common stock which are excluded from the table above as a result of the  limitation excludes an option to purchase an aggregate of  series x preferred stock due to the beneficial ownership limitation defined in item  excludes warrants defined in item  to purchase shares of common stock due to the beneficial ownership limitation the reporting persons may choose to convert or exercise as applicable the series x preferred stock series x preferred option defined in item  series x preferred stock defined in item  or warrants in other amounts among the reporting persons while continuing to comply with the beneficial ownership limitation see item a for a full description of the reporting person’s beneficial ownership      name of reporting person   bvf inc  check the appropriate box if a member of a group   a x   b o  sec use only    citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with  sole voting power    shares  shared voting power      sole dispositive power    shares  shared dispositive power      aggregate amount beneficially owned by each reporting person      check box if the aggregate amount in row  excludes certain shares   ¨  percent of class represented by amount in row       type of reporting person   co     consists of  series x preferred stock defined in item  convertible into approximately  shares of common stock assuming a series x conversion price defined in item  of  as of the date hereof the series x preferred stock conversion limitation described in the next sentence limits the aggregate conversion of series x preferred stock by the reporting persons the series x preferred stock may not be converted if after such conversion the reporting persons would beneficially own as determined in accordance with section d of the securities exchange act of  more than  of the number of shares of common stock then issued and outstanding in providing beneficial ownership described herein the reporting persons have assumed only certain series x preferred stock owned by bvf and bvf would be fully converted certain series x preferred stock held in the partners managed account would be partially converted and the remaining series x preferred stock owned by trading fund os would remain unconverted thereby bringing the reporting persons to the aggregate  limitation as such the reporting persons hold additional shares of series x preferred stock convertible into approximately  shares of common stock which are excluded from the table above as a result of the  limitation excludes an option to purchase an aggregate of  series x preferred stock due to the beneficial ownership limitation defined in item  excludes warrants defined in item  to purchase shares of common stock due to the beneficial ownership limitation the reporting persons may choose to convert or exercise as applicable the series x preferred stock series x preferred option defined in item  series x preferred stock defined in item  or warrants in other amounts among the reporting persons while continuing to comply with the beneficial ownership limitation see item a for a full description of the reporting person’s beneficial ownership    name of reporting person   mark n lampert  check the appropriate box if a member of a group   a x   b o  sec use only    citizenship or place of organization   united states number of shares beneficially owned by each reporting person with  sole voting power    shares  shared voting power      sole dispositive power    shares  shared dispositive power      aggregate amount beneficially owned by each reporting person      check box if the aggregate amount in row  excludes certain shares   ¨  percent of class represented by amount in row       type of reporting person   in     consists of  series x preferred stock defined in item  convertible into approximately  shares of common stock assuming a series x conversion price defined in item  of  as of the date hereof the series x preferred stock conversion limitation described in the next sentence limits the aggregate conversion of series x preferred stock by the reporting persons the series x preferred stock may not be converted if after such conversion the reporting persons would beneficially own as determined in accordance with section d of the securities exchange act of  more than  of the number of shares of common stock then issued and outstanding in providing beneficial ownership described herein the reporting persons have assumed only certain series x preferred stock owned by bvf and bvf would be fully converted certain series x preferred stock held in the partners managed account would be partially converted and the remaining series x preferred stock owned by trading fund os would remain unconverted thereby bringing the reporting persons to the aggregate  limitation as such the reporting persons hold additional shares of series x preferred stock convertible into approximately  shares of common stock which are excluded from the table above as a result of the  limitation excludes an option to purchase an aggregate of  series x preferred stock due to the beneficial ownership limitation defined in item  excludes warrants defined in item  to purchase shares of common stock due to the beneficial ownership limitation the reporting persons may choose to convert or exercise as applicable the series x preferred stock series x preferred option defined in item  series x preferred stock defined in item  or warrants in other amounts among the reporting persons while continuing to comply with the beneficial ownership limitation see item a for a full description of the reporting person’s beneficial ownership     item a name of issuer anthera pharmaceuticals inc a delaware corporation the “issuer” item b address of issuer’s principal executive offices  industrial boulevard suite b hayward california  item a name of person filing item b address of principal business office or if none residence item c citizenship biotechnology value fund lp “bvf”  sansome street th floor san francisco california  citizenship delaware biotechnology value fund ii lp “bvf”  sansome street th floor san francisco california  citizenship delaware biotechnology value trading fund os lp “trading fund os” po box  ugland house grand cayman ky cayman islands citizenship cayman islands bvf partners os ltd “partners os” po box  ugland house grand cayman ky cayman islands citizenship cayman islands bvf partners lp “partners”  sansome street th floor san francisco california  citizenship delaware bvf inc  sansome street th floor san francisco california  citizenship delaware mark n lampert “mr lampert”  sansome street th floor san francisco california  citizenship united states each of the foregoing is referred to as a “reporting person” and collectively as the “reporting persons”   item d title of class of securities common stock par value  per share the “common stock” item e cusip number u   item  if this statement is filed pursuant to rule db or db or c check whether the person filing is a   x not applicable   a   broker or dealer registered under section  of the exchange act   b   bank as defined in section a of the exchange act   c   insurance company as defined in section a of the exchange act   d   investment company registered under section  of the investment company act   e   an investment adviser in accordance with rule dbiie   f   an employee benefit plan or endowment fund in accordance with rule dbiif   g   a parent holding company or control person in accordance with rule dbiig   h   a savings association as defined in section b of the federal deposit insurance act   i   a church plan that is excluded from the definition of an investment company under section c of the investment company act   j   group in accordance with rule dbiij   k   group in accordance with rule dbiik if filing as a nonus institution in accordance with rule dbiij please specify the type of institution  item  ownership   a amount beneficially owned     the reporting persons hold  shares of series x preferred stock par value  per share the “series x preferred stock”  the series x preferred stock is convertible into common stock at a per share rate of one thousand  divided by the conversion price of the series x preferred stock the “series x conversion price” the series x conversion price will be equal to the lower of a  the closing price for the common stock as reported on nasdaq on september   or b the fiveday volumeweighted average price “vwap” of the issuer’s common stock over the five full trading days following the earlier of  the date of the issuer’s initial public announcement of topline andor efficacy data from the ongoing chablissc study or  if applicable the date of the issuer’s initial public announcement of the suspension including through the imposition of a clinical hold abandonment or other termination of the chablissc study assuming a series x conversion price of  the series x preferred stock would be convertible into an aggregate of approximately  shares of common stock       the series x preferred stock may not be converted if after such conversion the reporting persons would beneficially own as determined in accordance with section d of the securities exchange act of  the “exchange act” more than  of the number of shares of common stock then issued and outstanding the “series x beneficial ownership limitation” as of the date hereof the series x preferred stock beneficial ownership limitation described in the prior sentence limits the aggregate conversion by the reporting persons to approximately  shares of common stock underlying the series x preferred stock owned by the reporting persons in the aggregate   in providing beneficial ownership described herein the reporting persons have assumed only certain series x preferred stock owned by bvf and bvf would be fully converted certain series x preferred stock held in the partners managed account would be partially converted and the remaining series x preferred stock owned by trading fund os would remain unconverted thereby bringing the reporting persons to the aggregate series x beneficial ownership limitation   in addition to the series x preferred stock the reporting persons hold approximately  shares underlying certain warrants the “warrants”  the warrants will be exercised at a rate of  of the number of shares of common stock into which the series x preferred stock converts each warrant has an exercise price equal to the series x conversion price plus a  premium and will be exercisable at any time and from time to time after the date that is six months from the date of issuance and will expire thirty months from the first date it first becomes exercisable if the series x preferred stock were convertible into  shares of common stock the warrants would be exercisable to purchase  shares of common stock   the warrants may not be exercised if after such exercise the reporting persons would beneficially own as determined in accordance with the exchange act more than  of the number of shares of common stock then issued and outstanding the “warrant beneficial ownership limitation”   due to the warrant beneficial ownership limitation in providing beneficial ownership described herein the reporting persons have assumed that no warrants would be exercised   in addition to the series x preferred stock and warrants the reporting persons hold an option to purchase an aggregate of  shares of series x preferred stock par value  per share the “series x preferred stock” and the option to purchase the series x preferred stock the “series x preferred option”       the series x preferred stock is convertible into common stock at a rate of the lesser of i one thousand  divided by the product of the series x conversion price and onehundred and seventy five percent  and ii one thousand  divided by seventyfive percent  of the day vwap following the public announcement of certain topline data       the conversion price for the series x preferred stock will be equal to the lower of a  of the fiveday vwap of the issuer’s common stock over the five full trading days following the issuer’s initial public announcement of topline clinical efficacy and safety data from the issuer’s ongoing “solution” clinical study or b  of the thenapplicable conversion price for the series x preferred stock provided that the conversion price will in no event be lower than  the closing price for the common stock as reported on nasdaq on september   without the beneficial ownership limitation defined below the  shares of series x preferred stock is convertible into approximately  shares of common stock   the series x option may not be exercised if after such exercise the reporting persons would beneficially own as determined in accordance with the exchange act more than  of the number of shares of common stock then issued and outstanding the “series x beneficial ownership limitation” together with the “warrant beneficial ownership limitation” and the “series x preferred stock beneficial ownership limitation” the “beneficial ownership limitation”   due to the series x beneficial ownership limitation the reporting persons have assumed that the series x preferred option would not be converted   the reporting persons may choose to convert or exercise as applicable the series x preferred stock series x preferred option series x preferred stock or warrants in other amounts among the reporting persons while continuing to comply with the beneficial ownership limitation   as of the date hereof i bvf beneficially owned approximately  shares of common stock issuable upon the conversion of  shares of series x preferred stock held by it ii bvf beneficially owned approximately  shares of common stock issuable upon the conversion of  shares of series x preferred stock held by it and iii trading fund os beneficially owned  shares of common stock excluding approximately  shares of common stock issuable upon the conversion of  shares of series x preferred stock held by it due to the beneficial ownership limitation in each case assuming a series x conversion price of    partners os as the general partner of trading fund os may be deemed to beneficially own  shares of common stock beneficially owned by trading fund os   partners as the general partner of bvf bvf the investment manager of trading fund os and the sole member of partners os may be deemed to beneficially own the approximately  shares of common stock beneficially owned in the aggregate by bvf bvf trading fund os and a certain partners managed account the “partners managed account” including approximately  shares of common stock held in the partners managed account issuable upon the conversion of  shares of series x preferred stock and excluding approximately  shares of common stock held in the partners managed account due to the beneficial ownership limitation in total the partners managed account holds approximately  shares of common stock issuable upon the conversion of  shares of series x preferred stock       bvf inc as the general partner of partners may be deemed to beneficially own the  shares of common stock beneficially owned by partners   mr lampert as a director and officer of bvf inc may be deemed to beneficially own the  shares of common stock beneficially owned by bvf inc   the foregoing should not be construed in and of itself as an admission by any reporting person as to beneficial ownership of any shares of common stock owned by another reporting person partners os disclaims beneficial ownership of the shares of common stock beneficially owned by trading fund os each of partners bvf inc and mr lampert disclaims beneficial ownership of the shares of common stock beneficially owned by bvf bvf trading fund os and the partners managed account and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities   b percent of class   the following percentages are based on a denominator that is the sum of a  shares of common stock outstanding as disclosed in the issuer’s prospectus supplement on form b filed with the securities and exchange commission the “sec on september   and b  shares of common stock that may be acquired depending on certain events upon the conversion of certain series x preferred stock held by the reporting persons   as of the date hereof i bvf beneficially owned approximately  of the outstanding shares of common stock ii bvf beneficially owned approximately  of the outstanding shares of common stock iii trading fund os does not beneficially own any of the outstanding shares of common stock iv partners os does not beneficially own any of the outstanding shares of common stock and v each of partners bvf inc and mr lampert may be deemed to beneficially own approximately  of the outstanding shares of common stock approximately  of which is held in the partners managed account   c number of shares as to which such person has   i sole power to vote or to direct the vote   see cover pages items    ii shared power to vote or to direct the vote   see cover pages items        iii sole power to dispose or to direct the disposition of   see cover pages items    iv shared power to dispose or to direct the disposition of   see cover pages items  item  ownership of five percent or less of a class not applicable item  ownership of more than five percent on behalf of another person partners bvf inc and mr lampert share voting and dispositive power over the shares of common stock beneficially owned by bvf bvf and the partners managed account item  identification and classification of the subsidiary that acquired the security being reported on by the parent holding company or control person not applicable item  identification and classification of members of the group see exhibit  item  notice of dissolution of group not applicable item  certifications by signing below each of the undersigned certifies that to the best of its knowledge and belief the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect     signature after reasonable inquiry and to the best of his knowledge and belief each of the undersigned certifies that the information set forth in this statement is true complete and correct dated  september   biotechnology value fund lp             bvf inc by bvf partners lp its general partner       by bvf inc its general partner   by s mark n lampert         mark n lampert by s mark n lampert     president   mark n lampert         president               s mark n lampert         mark n lampert biotechnology value fund ii lp               by bvf partners lp its general partner       by bvf inc its general partner                 by s mark n lampert         mark n lampert         president                 bvf partners lp                 by bvf inc its general partner                 by s mark n lampert         mark n lampert         president       bvf partners os ltd                 by bvf partners lp its sole member       by bvf inc its general partner                 by s mark n lampert         mark n lampert         president                           biotechnology value trading fund os lp                 by bvf partners lp its investment manager       by bvf inc its general partner                 by s mark n lampert         mark n lampert         president           hedge fund resource center how to beat the market by  percentage points why track hedge funds download a free edition why you should dump your hedge funds  things you didnt know about hedge funds hot topics apple aapl latest stock news  company profile warren buffett news  analysis  portfolio  stock picks biggest insider purchases  sales news  analysis  data screener google goog latest stock news  company profile microsoft msft latest stock news  company profile home hedge funds markets blog authors about us contact us privacy policy terms of use site map all text and design is copyright  koala guide llc all rights reserved bvf partners lp acquires shares of xenon pharmaceuticals inc  marketwatch bulletin investor alert tokyo markets close in currencies europe markets london markets press release sept    pm edt bvf partners lp acquires shares of xenon pharmaceuticals inc san francisco california sep   marketwired via comtex  san francisco californiamarketwired  sep    bvf partners lp partners announced that on september   certain affiliates of partners acquired common shares the common shares of xenon pharmaceuticals inc xenon a burnaby british columbiabased company in a public offering collectively the transactions following these transactions the holdings of the various affiliates are as follows biotechnology value fund lp bvf ownership of  common shares representing approximately  of the issued and outstanding common shares from common shares representing approximately  of the then issued and outstanding common shares prior to the transaction biotechnology value fund ii lp bvf ownership of  common shares representing approximately  of the issued and outstanding common shares from common shares representing approximately  of the then issued and outstanding common shares prior to the transaction biotechnology trading fund os lp trading fund os ownership of  common shares representing approximately  of the issued and outstanding common shares from common shares representing approximately  of the then issued and outstanding common shares prior to the transaction investment llc ill ownership of  common shares representing approximately  of the issued and outstanding common shares from common shares representing approximately  of the then issued and outstanding common shares prior to the transaction msi bvf spv llc msi ownership of  common shares representing approximately  of the issued and outstanding common shares from common shares representing approximately  of the then issued and outstanding common shares prior to the transaction partners as the general partner of bvf and bvf the investment manager of msi and ill and the sole member of bvf partners os ltd which is itself the general partner of trading fund os may be considered to have the power to exercise control or direction over the common shares beneficially owned in the aggregate by bvf bvf trading fund os ill and msi partners has purchased shares from the issuer for investment purposes and in the future may further purchase hold vote trade dispose or otherwise deal in the common shares of the issuer in such manner as they deem advisable to benefit from changes in market prices of such common shares publically disclosed changes in the operations of the issuer its business strategy or prospects or from a sale or merger of the issuer partners is located at  sansome street th floor san francisco california  xenons head office is located at  gilmore way burnaby british columbia vg w bvf partners lp   �  nasdaq inc all rights reserved most popular  cocacola to replace coke zero in us  if you can buy only one stock or etf make it this one  market snapshot stock market ends at record on robust earnings as fed issues policy update  outside the box the apple car could run traditional automakers off the road  barrons buzz how to fix wall street and bankers pay find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest psamsung posts record profits on back of strong galaxy s sales pfor transgender americans workplace discrimination isn’t limited to the military pscaramucci on washington back stabbers ‘i’m more of a frontstabbing person’ pfacebook keeps warning about growth but growth doesn’t stop pfacebook heads toward  billion market cap after earnings pfoxconn pledges to build  billion stateoftheart electronics plant in wisconsin pgraham says trump is showing weakness in unilateral public spat with sessions pfacebook hits  billion users earnings beat boosts stock live blog recap pnew rules for ftse russell index provider to exclude snap others from benchmarks pthe nintendo switch’s sellout launch in many charts p coworkers you should avoid like the plague in meetings pcommunity health systems shares fall after profit warning pwhat donald trump’s battle of wills with jeff sessions teaches you about a difficult boss pstock market ends at record on robust earnings as fed issues policy update ptrump puts his hands together for ‘the late great abraham lincoln’ pyear treasury yield falls the most in five weeks after fed statement pyour k match may have some strings attached pthis is the worst mistake people make at work pwhy equalweighted stockmarket indexes bounce back faster from bear markets pnutrisystem shares rally on betterthanexpected earnings loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  secgems form   data feeds now available excel  csv  java  python etc database learn more     ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  filing date june   period ending june   date of filing date change june   signed by bvf partners lp by bvf inc its general partner by mark n lampert president biotechnology value fund lp by bvf partners lp its general partner by bvf inc its general partner by mark n lampert president biotechnology value fund ii lp by bvf partners lp its general partner by bvf inc its general partner by mark n lampert president bvf partners os ltd by bvf partners lp its sole member by bvf inc its general partner by mark n lampert president biotechnology value trading fund os lp by bvf partners lp its investment manager bvf inc its general partner by mark n lampert president bvf inc by mark n lampert president mark n lampert accession number  type  public document count  key documents and exhibits link type id filename ownership document   formxml issuer xenon pharmaceuticals inc xene reporting owner bvf partners l pil  owner biotechnology value fund l p other see explanation of responses biotechnology value fund ii lp other see explanation of responses biotechnology value trading fund os lp other see explanation of responses bvf partners os ltd other see explanation of responses bvf incil  owner lampert mark n  owner date of event req stmt  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead f this form  is filed jointly by biotechnology value fund lp bvf biotechnology value fund ii lp bvf biotechnology value trading fund os lp trading fund os bvf partners os ltd partners os bvf partners lp partners bvf inc and mark n lampert collectively the reporting persons each of the reporting persons is a member of a section d group that collectively owns more than  of the issuers outstanding shares of common stock each of the reporting persons disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his or its pecuniary interest therein f shares of common stock owned directly by bvf as the general partner of bvf partners may be deemed to beneficially own the shares of common stock owned directly by bvf as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the shares of common stock owned directly by bvf as a director and officer of bvf inc mr lampert may be deemed to beneficially own the shares of common stock owned directly by bvf f shares of common stock owned directly by bvf as the general partner of bvf partners may be deemed to beneficially own the shares of common stock owned directly by bvf as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the shares of common stock owned directly by bvf as a director and officer of bvf inc mr lampert may be deemed to beneficially own the shares of common stock owned directly by bvf f shares of common stock owned directly by trading fund os as the general partner of trading fund os partners os may be deemed to beneficially own the shares of common stock owned directly by trading fund os as the investment manager of trading fund os and the sole member of partners os partners may be deemed to beneficially own the shares of common stock owned directly by trading fund os as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the shares of common stock owned directly by trading fund os as a director and officer of bvf inc mr lampert may be deemed to beneficially own the shares of common stock owned directly by trading fund os signed by  bvf partners lp by bvf inc its general partner by s mark n lampert president  on   biotechnology value fund lp by bvf partners lp its general partner by bvf inc its general partner by s mark n lampert president  on   biotechnology value fund ii lp by bvf partners lp its general partner by bvf inc its general partner by s mark n lampert president  on   bvf partners os ltd by bvf partners lp its sole member by bvf inc its general partner by s mark n lampert president  on   biotechnology value trading fund os lp by bvf partners lp its investment manager bvf inc its general partner by s mark n lampert president  on   bvf inc by s mark n lampert president  on   s mark n lampert  on  type filing company sic rel irs  state of inc fy end mailing address former filing vals issuer xenon pharmaceuticals inc cik     gilmore way burnaby  a  vg w   canada  pharmaceutical preparations  canada  a      gilmore way burnaby  a  vg w   canada type filing reporting owner company sic rel irs  state of inc fy end mailing address former filing vals reporting owner bvf partners os ltd  cik   state of inc cayman islands  e  fy end cik po box  ugland house grand cayman  e  ky   cayman islands po box  ugland house grand cayman  e  ky   cayman islands form type act file number film number reporting owner biotechnology value trading fund os lp  cik   state of inc cayman islands  e  fy end cik po box  ugland house grand cayman  e  ky   cayman islands po box  ugland house grand cayman  e  ky   cayman islands form type act file number film number reporting owner biotechnology value fund ii lp  cik   state of inc usa  de  fy end cik  sansome st th fl san francisco  ca     usa  sansome st th fl san francisco  ca     usa form type act file number film number reporting owner biotechnology value fund l p  cik   sic  state of inc usa  de  fy end cik  sansome st th fl san francisco  ca     usa  sansome st th fl san francisco  ca     usa form type act file number film number reporting owner lampert mark n  cik   cik  sansome st th fl san francisco  ca     usa form type act file number film number reporting owner bvf incil  cik   state of inc usa  de  fy end cik  sansome st th fl san francisco  ca     usa  sansome st th fl san francisco  ca     usa form type act file number film number reporting owner bvf partners l pil  cik   cik  sansome st th fl san francisco  ca     usa  sansome st th fl san francisco  ca     usa form type act file number film number statement of changes in beneficial ownership  support   newswire  home  log in boards stocks commodities forex cryptocurrency the lounge hot breakout boards ihub my stocks activity ticker buzz cloud most read most posted most followed members recent news active boards site stats new boards cannabis stocks tools data tools  charts trader alerts trades portfolio top lists price  news alerts commodities markets in d newswire more tools  newsletters my image gallery advanced search videos all news stock screener news filter live charts live news live desktop forex prices commodities etf center educational channel personal finance qa streamer level  follow feed quotechartlevel tradesnewsfinancialshistoricaltechnical analysismessage boardcti biopharma corp mm nasdaqcti biopharmabitcti biopharmabita statement of changes in beneficial ownership  date    pm source  edgar us regulatory stock  cti biopharma corp mm ctic quote       pm statement of changes in beneficial ownership tweet print form    check this box if no longer subject to section  form  or form  obligations may continue see instruction b          united states securities and exchange commission washington dc  statement of changes in beneficial ownership of securities                                                                                    omb approval omb number  estimated average burden hours per response                         filed pursuant to section a of the securities exchange act of  or section h of the investment company act of                          name and address of reporting person  bvf partners l pil  issuer name and ticker or trading symbol cti biopharma corp  ctic   relationship of reporting persons to issuer check all applicable  director                       x   owner  officer give title below       other specify below last          first          middle  sansome st th fl  date of earliest transaction mmddyyyy  street san francisco ca  city        state        zip  if amendment date original filed mmddyyyy    individual or jointgroup filing check applicable line  form filed by one reporting person  x  form filed by more than one reporting person table i  nonderivative securities acquired disposed of or beneficially owned title of security instr   trans date a deemed execution date if any  trans code instr   securities acquired a or disposed of d instr   and   amount of securities beneficially owned following reported transactions instr  and   ownership form direct d or indirect i instr   nature of indirect beneficial ownership instr  code v amount a or d price common stock no par value per share         c         a       d      common stock no par value per share         c         a       d      common stock no par value per share         c         a       d      common stock no par value per share         c         a       i    please see footnote    table ii  derivative securities beneficially owned  eg  puts calls warrants options convertible securities  title of derivate security instr   conversion or exercise price of derivative security  trans date a deemed execution date if any  trans code instr   number of derivative securities acquired a or disposed of d instr   and   date exercisable and expiration date  title and amount of securities underlying derivative security instr  and   price of derivative security instr   number of derivative securities beneficially owned following reported transactions instr   ownership form of derivative security direct d or indirect i instr   nature of indirect beneficial ownership instr  code v a d date exercisable expiration date title amount or number of shares series n preferred stock no par value per share            p                   common stock no par value per share               d      series n preferred stock no par value per share            p                   common stock no par value per share               d      series n preferred stock no par value per share            p                   common stock no par value per share               d      series n preferred stock no par value per share            p                   common stock no par value per share               i    please see footnote    series n preferred stock no par value per share            c                   common stock no par value per share               d      series n preferred stock no par value per share            c                   common stock no par value per share               d      series n preferred stock no par value per share            c                   common stock no par value per share               d      series n preferred stock no par value per share            c                   common stock no par value per share               i    please see footnote    explanation of responses   this form  is filed jointly by biotechnology value fund lp bvf biotechnology value fund ii lp bvf biotechnology value trading fund os lp trading fund os bvf partners os ltd partners os bvf partners lp partners bvf inc and mark n lampert collectively the reporting persons each of the reporting persons is a member of a section d group that collectively owns more than  of the issuers outstanding shares of common stock each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein   securities owned directly by bvf as the general partner of bvf partners may be deemed to beneficially own the securities owned directly by bvf as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the securities owned directly by bvf as a director and officer of bvf inc mr lampert may be deemed to beneficially own the securities owned directly by bvf   securities owned directly by bvf as the general partner of bvf partners may be deemed to beneficially own the securities owned directly by bvf as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the securities owned directly by bvf as a director and officer of bvf inc mr lampert may be deemed to beneficially own the securities owned directly by bvf   securities owned directly by trading fund os as the general partner of trading fund os partners os may be deemed to beneficially own the securities owned directly by trading fund os as the investment manager of trading fund os and the sole member of partners os partners may be deemed to beneficially own the securities owned directly by trading fund os as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the securities owned directly by trading fund os as a director and officer of bvf inc mr lampert may be deemed to beneficially own the securities owned directly by trading fund os   securities held in certain partners managed accounts the partners managed accounts partners as the investment manager of the partners managed accounts may be deemed to beneficially own the securities held by the partners managed accounts   the issuers series n preferred stock preferred stock has no expiration date and are convertible upon issuance provided however that the beneficial ownership conversion limit defined below has not been reached by an exchanging stockholder the reporting persons purchased a total of  shares of preferred stock after the conversion of  preferred stock the reporting persons reached the beneficial ownership conversion limit defined below accordingly  shares of preferred stock have not been converted to common stock   this form  is filed in connection with the purchase by the reporting persons of a total of  shares of preferred stock convertible for a total of approximately  shares of common stock pursuant to the terms of the preferred stock offering the reporting persons have an ongoing right to convert the preferred stock accordingly on june   the reporting persons converted an aggregate of  shares of preferred stock into approximately  shares of common stock at a conversion price of  per share of underlying common stock the conversion price provided however certain of the preferred stock could not be converted by the reporting persons because the reporting persons may be deemed to beneficially own  of the issued and outstanding common stock calculated as provided in the certificate of designation establishing the preferred stock the beneficial ownership conversion limit   preferred stock defined above with a stated value of  per share the stated value are convertible into common stock at a ratio determined by dividing the stated value by the conversion price reporting owners reporting owner name  address relationships director  owner officer other bvf partners l pil  sansome st th fl san francisco ca  x biotechnology value fund l p  sansome st th fl san francisco ca  see explanation of responses biotechnology value fund ii lp  sansome st th fl san francisco ca  see explanation of responses biotechnology value trading fund os lp po box  ugland house grand cayman e ky see explanation of responses bvf partners os ltd po box  ugland house grand cayman e ky see explanation of responses bvf incil  sansome st th fl san francisco ca  x lampert mark n  sansome st th fl san francisco ca  x signatures bvf partners lp by bvf inc its general partner by s mark n lampert president   signature of reporting person date biotechnology value fund lp by bvf partners lp its general partner by bvf inc its general partner by s mark n lampert president   signature of reporting person date biotechnology value fund ii lp by bvf partners lp its general partner by bvf inc its general partner by s mark n lampert president   signature of reporting person date bvf partners os ltd by bvf partners lp its sole member by bvf inc its general partner by s mark n lampert president   signature of reporting person date biotechnology value trading fund os lp by bvf partners lp its investment manager bvf inc its general partner by s mark n lampert president   signature of reporting person date bvf inc by s mark n lampert president   signature of reporting person date s mark n lampert   signature of reporting person date reminder report on a separate line for each class of securities beneficially owned directly or indirectly  if the form is filed by more than one reporting person see instruction bv  intentional misstatements or omissions of facts constitute federal criminal violations see  usc  and  usc ffa note file three copies of this form one of which must be manually signed if space is insufficient see instruction  for procedure persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid omb control number cti biopharma corp nasdaqctichistorical stock chart  year  from jul  to jul  cti biopharma corp nasdaqcticintraday stock chart today  wednesday  july  latest ctic messages view more posts remove from favorites add to favorites  message board see more message board posts your recent history lse gkp gulf keyst lse qpp quindell ftse ukx ftse  lse iof iofina fx gbpusd uk sterlin stocks youve viewed will appear in this box letting you easily return to quotes youve seen previouslyregister now to create your own custom streaming stock watchlist nyse amex and asx quotes are delayed by at least  minutesall other quotes are delayed by at least  minutes unless otherwise stated secgems form   data feeds now available excel  csv  java  python etc database learn more     ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  filing date june   period ending june   date of filing date change june   signed by bvf partners lp by bvf inc its general partner by mark n lampert president biotechnology value fund lp by bvf partners lp its general partner by bvf inc its general partner by mark n lampert president biotechnology value fund ii lp by bvf partners lp its general partner by bvf inc its general partner by mark n lampert president bvf partners os ltd by bvf partners lp its sole member by bvf inc its general partner by mark n lampert president biotechnology value trading fund os lp by bvf partners lp its investment manager bvf inc its general partner by mark n lampert president bvf inc by mark n lampert president mark n lampert accession number  type  public document count  key documents and exhibits link type id filename ownership document   formxml issuer xenon pharmaceuticals inc xene reporting owner bvf partners l pil  owner biotechnology value fund l p other see explanation of responses biotechnology value fund ii lp other see explanation of responses biotechnology value trading fund os lp other see explanation of responses bvf partners os ltd other see explanation of responses bvf incil  owner lampert mark n  owner date of event req stmt  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead nonderriv transcommon stock no par value per sharep  open market or private purchasefalsead f this form  is filed jointly by biotechnology value fund lp bvf biotechnology value fund ii lp bvf biotechnology value trading fund os lp trading fund os bvf partners os ltd partners os bvf partners lp partners bvf inc and mark n lampert collectively the reporting persons each of the reporting persons is a member of a section d group that collectively owns more than  of the issuers outstanding shares of common stock each of the reporting persons disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his or its pecuniary interest therein f shares of common stock owned directly by bvf as the general partner of bvf partners may be deemed to beneficially own the shares of common stock owned directly by bvf as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the shares of common stock owned directly by bvf as a director and officer of bvf inc mr lampert may be deemed to beneficially own the shares of common stock owned directly by bvf f shares of common stock owned directly by bvf as the general partner of bvf partners may be deemed to beneficially own the shares of common stock owned directly by bvf as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the shares of common stock owned directly by bvf as a director and officer of bvf inc mr lampert may be deemed to beneficially own the shares of common stock owned directly by bvf f shares of common stock owned directly by trading fund os as the general partner of trading fund os partners os may be deemed to beneficially own the shares of common stock owned directly by trading fund os as the investment manager of trading fund os and the sole member of partners os partners may be deemed to beneficially own the shares of common stock owned directly by trading fund os as the investment adviser and general partner of partners bvf inc may be deemed to beneficially own the shares of common stock owned directly by trading fund os as a director and officer of bvf inc mr lampert may be deemed to beneficially own the shares of common stock owned directly by trading fund os signed by  bvf partners lp by bvf inc its general partner by s mark n lampert president  on   biotechnology value fund lp by bvf partners lp its general partner by bvf inc its general partner by s mark n lampert president  on   biotechnology value fund ii lp by bvf partners lp its general partner by bvf inc its general partner by s mark n lampert president  on   bvf partners os ltd by bvf partners lp its sole member by bvf inc its general partner by s mark n lampert president  on   biotechnology value trading fund os lp by bvf partners lp its investment manager bvf inc its general partner by s mark n lampert president  on   bvf inc by s mark n lampert president  on   s mark n lampert  on  type filing company sic rel irs  state of inc fy end mailing address former filing vals issuer xenon pharmaceuticals inc cik     gilmore way burnaby  a  vg w   canada  pharmaceutical preparations  canada  a      gilmore way burnaby  a  vg w   canada type filing reporting owner company sic rel irs  state of inc fy end mailing address former filing vals reporting owner lampert mark n  cik   cik  sansome st th fl san francisco  ca     usa form type act file number film number reporting owner bvf incil  cik   state of inc usa  de  fy end cik  sansome st th fl san francisco  ca     usa  sansome st th fl san francisco  ca     usa form type act file number film number reporting owner bvf partners os ltd  cik   state of inc cayman islands  e  fy end cik po box  ugland house grand cayman  e  ky   cayman islands po box  ugland house grand cayman  e  ky   cayman islands form type act file number film number reporting owner biotechnology value trading fund os lp  cik   state of inc cayman islands  e  fy end cik po box  ugland house grand cayman  e  ky   cayman islands po box  ugland house grand cayman  e  ky   cayman islands form type act file number film number reporting owner biotechnology value fund ii lp  cik   state of inc usa  de  fy end cik  sansome st th fl san francisco  ca     usa  sansome st th fl san francisco  ca     usa form type act file number film number reporting owner biotechnology value fund l p  cik   sic  state of inc usa  de  fy end cik  sansome st th fl san francisco  ca     usa  sansome st th fl san francisco  ca     usa form type act file number film number reporting owner bvf partners l pil  cik   cik  sansome st th fl san francisco  ca     usa  sansome st th fl san francisco  ca     usa form type act file number film number microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft biotech bull  bear x etf  labu labd  direxion brzu daily msci brazil bull x shareschad daily csi  china a share bear x shareschau daily csi  china a share bull x sharesclaw daily homebuilders  supplies bear x sharescom direxion auspice broad commodity strategy etfcure daily healthcare bull x sharescweb daily csi china internet index bull x sharesdfen daily aerospace  defense bull x sharesdpk daily msci developed markets bear x sharesdpst daily regional banks bull x sharesdrip daily sp oil  gas exp  prod bear x sharesdrn daily msci real estate bull x sharesdrv daily msci real estate bear x sharesdull daily silver miners index bear x sharesdusl daily industrials bull x sharesdust daily gold miners index bear x sharesdxcbx direxion indexed cvt strategy funddxcix direxion indexed commodity strategy fund – instdxctx direxion indexed commodity strategy fund – adxelx monthly emerging markets bull x funddxhlx monthly china bull x funddxhyx monthly high yield bull x funddxklx monthly  year treasury bull x funddxksx monthly  year treasury bear x funddxltx monthly  year treasury bull x funddxmax direxion indexed managed futures strategy fund – adxmcx direxion indexed managed futures strategy fund – cdxmix direxion indexed managed futures strategy fund – instdxnlx monthly nasdaq bull x funddxnsx monthly nasdaq bear x funddxqlx monthly nasdaq bull x funddxrlx monthly small cap bull x funddxrsx monthly small cap bear x funddxscx direxion indexed commodity strategy fund – cdxslx monthly sp  bull x funddxssx monthly sp  bear x funddxstx monthly  year treasury bear x funddzk daily msci developed markets bull x sharesedc daily msci emerging markets bull x sharesedz daily msci emerging markets bear x shareserx daily energy bull x sharesery daily energy bear x shareseryy daily energy bear x shareseufl daily msci european financials bull x shareseufs daily msci european financials bear x shareseurl daily ftse europe bull x shareseuxl daily euro stoxx  bull x sharesfas daily financial bull x sharesfaz daily financial bear x sharesfazz daily financial bear x sharesgasl daily natural gas related bull x sharesgasx daily natural gas related bear x sharesgush daily sp oil  gas exp  prod bull x shareshakk daily cyber security  it bull x shareshcyax direxion hilton tactical income fund – a shareshcycx direxion hilton tactical income fund – c shareshcyix direxion hilton tactical income fund – institutionalhydd daily high yield bear x sharesibln direxion ibillionaire index etfindl daily msci india bull x sharesjdst daily junior gold miners index bull x sharesjdst daily junior gold miners index bear x sharesjpnl daily msci japan bull x sharesknow direxion all cap insider sentiment shareskoru daily msci south korea bull x shareslabd daily sp biotech bear x shareslabs daily sp biotech bear x shareslabu daily sp biotech bull x shareslbj daily latin america bull x sharesllsc daily small cap bull x sharesllsp daily sp  bull x sharesmelt daily gold miners index bear x sharesmexx daily msci mexico bull x sharesmidu daily mid cap bull x sharesmidz daily mid cap bear x sharesnail daily homebuilders  supplies bull x sharesnugt daily gold miners index bull x sharespemvx evolution managed fundsqqqe direxion nasdaq equal weighted index sharesretl daily retail bull x sharesrusl daily russia bull x sharesruss daily russia bear x sharessagg daily total bond market bear x sharesshny daily silver miners index bull x sharessick daily healthcare bear x sharessmll daily small cap bull x sharessoxl daily semiconductor bull x sharessoxs daily semiconductor bear x sharesspdn daily sp  bear x sharessplz daily consumer staples bear x sharesspuu daily sp  bull x sharesspxl daily sp  bull x sharesspxs daily sp  bear x sharestecl daily technology bull x sharestecs daily technology bear x sharestecz daily technology bear x sharestmf daily  year treasury bull x sharestmv daily  year treasury bear x sharestna daily small cap bull x sharestpor daily transportation bull x sharestybs daily  year treasury bear x sharestyd daily  year treasury bull x sharestyns daily  year treasury bear x sharestyo daily  year treasury bear x sharestza daily small cap bear x sharesutlz daily utilities bear x sharesutsl daily utilities bull x shareswdrw daily regional banks bear x sharesyang daily ftse china bear x sharesyinn daily ftse china bull x shareszmlp direxion zacks mlp high income index shares direxion daily sp biotech bull and bear x shares fund symbol labu daily target  intraday indicative value labuiv bloomberg index spsibitr cusip k isin usk expense ratio grossnet     inception date may   fund symbol labd daily target  intraday indicative value labdiv bloomberg index spsibitr cusip k isin usk expense ratio grossnet     inception date may   overview the direxion daily sp biotech bull and bear x shares seek daily investment results before fees and expenses of  or  of the inverse or opposite of the performance of the sp biotechnology select industry index there is no guarantee the funds will meet their stated investment objectives these leveraged etfs seek a return that is  or  of the return of their benchmark index for a single day the funds should not be expected to provide three times or negative three times the return of the benchmark’s cumulative return for periods greater than a day labu labd fact sheet etf guide labu prospectus labd prospectus premium discount daily holdings download labu daily holdings csv download labd daily holdings csv daily holdings labu     daily sp biotech bull x shares trade date     shares outstanding  stock ticker security description shares price market value — bank of new york cash reserve    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — goldman finl sq trsry inst     — goldman finl sq trsry inst     — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    xbi spdr sp biotech etf    labd     daily sp biotech bear x shares trade date     shares outstanding  stock ticker security description shares price market value — bank of new york cash reserve    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — goldman finl sq trsry inst     — goldman finl sq trsry inst     — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    strategy  benefits key benefits you know that trading is different than investing but the opportunity to take advantage of shortterm trends is only won if you get the direction right whether you’re a bull or a bear direxion is with you our leveraged etfs are powerful tools built to help you magnify your shortterm perspective with daily x leverage go where there’s opportunity with bull and bear funds for both sides of the trade and stay agile – with liquidity to trade through rapidly changing markets leveraged and inverse etfs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage they seek daily goals and should not be expected to track the underlying index over periods longer than one day they are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments target index the sp biotechnology select industry index spsibitr is provided by standard  poor’s and includes domestic companies from the biotechnology industry the index is designed to measure the performance of the biotechnology subindustry based on the global industry classification standards gics one cannot directly invest in an index index top ten holdings  clovis oncology inc  exelixis inc  kite pharma inc  alexion pharmaceuticals inc  celgene corp  alnylam pharmaceuticals inc  gilead sciences inc  sarepta therapeutics inc  bioverativ inc  exact sciences corp  index sector weightings  medicalbiomedicalgenetics  medicaldrugs  therapeutics  medicalgeneric drugs  diagnostic kits  medical products  diagnostic equipment  drug delivery systems  index data as of  source bloomberg index sector weightings and top holdings are subject to change tax reporting supplemental tax documents  – ordinary income from us government obligations labd pricing and performance pricing and performance nav and market price information as of july   line chart shows pricing trend over the last  days fund symbol labu net asset value nav  nav   change   change  market price closing  market   change   change  premium  discount   change from last day trading fund symbol labd net asset value nav  nav   change   change  market price closing  market   change   change  premium  discount   change from last day trading monthly quarterly as of june   as of june   labu daily sp biotech bull x shares m  m  ytd  y  since inception inception date expense ratio  gross  net  m  m  ytd  y  since inception inception date expense ratio  gross  net  nav          market close      nav          market close      spsibitr benchmark index        labd daily sp biotech bear x shares m  m  ytd  y  since inception inception date expense ratio  gross  net  m  m  ytd  y  since inception inception date expense ratio  gross  net  nav          market close      nav          market close      spsibitr benchmark index         the net expense ratio includes management fees other operating expenses and acquired fund fees and expenses if acquired fund fees and expenses were excluded the net expense ratio would be  the funds’ adviser rafferty asset management llc “rafferty” has entered into an operating expense limitation agreement with each fund under which rafferty has contractually agreed to cap all or a portion of its management fee andor reimburse each fund for other expenses through september   to the extent that the fund’s total annual fund operating expenses exceed  of the fund’s daily net assets other than the following taxes swap financing and related costs acquired fund fees and expenses dividends or interest on short positions other interest expenses brokerage commissions and extraordinary expenses if these expenses were included the expense ratio would be higher the performance data quoted represents past performance past performance does not guarantee future results the investment return and principal value of an investment will fluctuate an investor’s shares when redeemed may be worth more or less than their original cost current performance may be lower or higher than the performance quoted returns for performance under one year are cumulative not annualized for the most recent monthend performance please visit the funds website at direxioninvestmentscom shortterm performance in particular is not a good indication of the fund’s future performance and an investment should not be made based solely on returns because of ongoing market volatility fund performance may be subject to substantial shortterm changes for additional information see the fund’s prospectus distributions distributions labu daily sp biotech bull x shares there are no recent distributions available for this fund labd daily sp biotech bear x shares there are no recent distributions available for this fund related reading knowledge related education articles and insights etf market pricing etf market prices are the prices at which investors buy or sell shares of an etf in the secondary market while etfs are designed to trade in line with their intraday values during times of significant market volatility an etf’s market price may vary more widely from its intraday value etf liquidity – four rules to consider liquidity transparency realtime trading and relatively low management fees are the reason why etfs are becoming more and more popular learn about the four key characteristics that investors should better understand in order to trade them properly more articles like this microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft hughes optioneering the options trade you can make today with just  free strategy guide reveals how to start trading options on a shoestring budget download now copyright   chuck hughes  all rights reserved privacy policy    contact us    earnings disclaimer dont miss your free ebook enter your email below and get started withoptions trading made easy wait you forgot your free ebook enter your email below and get started withoptions trading made easy ld products  coupon code and up to  off printer ink  ld products we detected that your javascript seem to be disabled you must have javascript enabled in your browser to utilize the functionality of this website tax season sale  off ink and toner shop now quick reorder track order government my printers help  create account or sign in free shipping on all orders over † lifetime  satisfaction guarantee free shipping on orders over † low flat rate shipping  only  on orders under † multiple fulfillment centers  so you get your order faster orders placed before pm usually ship the same day †applies to orders delivered to the contiguous us close learn more reliability for a lifetime  all of our ld brand compatible ink and toner cartridges are backed by a lifetime guarantee verified excellence  our cartridges have been tested for performance quality and page yield so you know you are getting the absolute best product available your happiness matters  in the event that you are dissatisfied with your purchase simply let us know  well do our best to make it right close learn more special offers  items ink  toner office supplies paper cleaning  breakroom technology office furniture featured ink  toner brands all categories hp canon epson brother lexmark dell xerox samsung more ink  toner brands konica pitney bowes kyocera ricoh kodak sharp okidata toshiba panasonic refill kits featured office supply categories all categories writing  correction general supplies binders  accessories filing supplies envelopes  forms calendars  planners boards  easels desk organizers more office supply categories bags  travel accessories mailing  shipping storage  organizers tools  equipment cash handling labeling  labeling systems teaching  art featured paper categories all categories copy  multiuse paper notebooks pads  filler paper adhesive note pads photo paper brochure  specialty paper cards  stationary colored paper wide format paper featured cleaning  breakroom categories all categories cleaning supplies cleaning equipment breakroom supplies healthcare supplies safety  security facility supplies climate control featured technology categories all categories printers office machines  electronics power  backup network  cables d printing peripherals  memory drives  media shredders  accessories more technology categories audio video players computer accessories radio  mobile technology software  utilities cameras  scanners ink refill kits telephone  communication multimedia players displays  digital projectors featured office furnitures categories all categories furniture collections desks  tables chairs chair mats  accessories office decor  lighting armoires  bookcases filing storage  accessories carts  stands furniture accessories panel systems  accessories menu call reorder cart ink  toner office supplies hp canon epson brother lexmark dell xerox samsung okidata konica shop all printer brands office supplies paper cleaning technology office furniture ink  toner office supplies paper cleaning  breakroom technology office furniture my printers sign in track your order create account help special offers back general office supplies ink  toner hp canon epson brother lexmark dell xerox samsung okidata konica shop all printer brands  off ink  toner plus free shipping on all orders over  coupon code ldp applied expires  excludes oem items applies to orders delivered to the contiguous us scroll down for details find printer supplies fast easy  hassle free ink  toner finder select a printer brand select a printer brand top brands brother canon epson hewlett packard hp lexmark xerox all brands az acom amt amano astrojet birmy graphics brother bryce canon casio compaq computer language res copystar dec dataproducts dell dymo eicon laser electronic forms epson gestetner hasler hewlett packard hp ibm infoprint imagen imagistics interface systems kodak konicaminolta kyoceramita lanier lasermaster lexmark mimaki muratec mutoh nec nashuatec neopost newgen north atlantic oce okidata olivetti olympia panasonic pitney bowes primera printronix rena ricoh riso risograph roland samsung savin secap sharp sindoh star micronics tallygenicom tandem telenorma tenofax texas instruments toshiba xerox brother canon epson hewlett packard hp lexmark xerox acom amt amano astrojet birmy graphics brother bryce canon casio compaq computer language res copystar dec dataproducts dell dymo eicon laser electronic forms epson gestetner hasler hewlett packard hp ibm infoprint imagen imagistics interface systems kodak konicaminolta kyoceramita lanier lasermaster lexmark mimaki muratec mutoh nec nashuatec neopost newgen north atlantic oce okidata olivetti olympia panasonic pitney bowes primera printronix rena ricoh riso risograph roland samsung savin secap sharp sindoh star micronics tallygenicom tandem telenorma tenofax texas instruments toshiba xerox select a printerfamily select a printer family select a printer model select a printer model submit shop ink  toner from these top printer brands shop by printer brand hp hp officejet pro  hp officejet pro  hp envy  shop hp ink canon canon pixma mx canon pixma mg canon pixma mg shop canon ink epson epson workforce wf epson workforce wf epson workforce wf shop epson ink brother brother mfcjdw brother mfcjdw brother mfcjdw shop brother ink lexmark lexmark x lexmark prospect pro lexmark pro shop lexmark ink dell dell vw dell hcdw dell cw color shop dell ink xerox xerox phaser  xerox workcentre  xerox workcentre  shop xerox ink samsung samsung xpress cw samsung xpress mfw samsung xpress cfw shop samsung ink konicaminolta konica bizhub ce konica bizhub ce konica pagepro mf shop konica ink okidata okidata microline  turbo okidata mbw okidata oki mcw shop okidata ink shop all printer brands adding to cart added to cart add to get free shipping your order qualifies for free shipping price qty subtotal free shipping on orders over  to the contiguous us orders placed before pm pst typically ship the same day cart summary edit cart items in cart estimated shipping contiguous us ships same day coupon will be applied in shopping cart view cart continue shopping customers also bought other social login facebook sign in google sign in linkedin sign in search engine marketing sem  bing ads skip to content sign upsign in   you run your business well help find your customers bing ads can help build your business and drive your success spend  and get  in advertising credit† †offer details get  in search advertising when you spend  in bing ads coupon code class first name last name email your website url business phone required microsoft may contact you to provide updates and special offers about bing ads you can unsubscribe at any time to learn more you can read the privacy statement type the code from the image enter security code   × get  in search advertising when you spend  in bing ads †offer details offer expires december   valid only for new bing ads customers who are first party recipients of the offer email a new bing ads customer is one that has not advertised on bing ads before enter promotional coupon code and spend  applies to threshold and prepaid accounts to receive  in bing ads credits limit one promotion code per new bing ads customer promotional code must be redeemed within thirty  days of bing ads new customer account creation ad campaign costs accrued before receiving a credit as well as costs accrued after all credits are used will be charged to the payment method associated with the bing ads account if customer payment fails the coupon amount will not be applied ads will continue to run and accrue costs after any promotional credit has been used up any portion of the credit not used within ninety  days of credit redemption will expire and cant be carried over even if the bing ads customer switches their payment method offer valid only to residents of the united states in order for the offer to be valid a form of payment must be entered into your account prior to redemption of the promotional code and prior to your account going live to take advantage of the credit this offer may not be combined with any other offer promotional code coupon or discount separated redeemed for cash transferred sold or bartered microsoft in its sole discretion can close your account for any suspected coupon abuse refund of the  is not permitted see bing ads terms and conditions for more details at signup other terms and conditions may apply microsoft reserves the right to cancel change or suspend this offer at any time without notice see how bing ads works customers search customers see your ad customers contact you watch how bing ads works     × how bing ads works help more customers find you see how bing can attract customers your google adwords campaigns cant reach  million searchers on the bing network tap into  of the search marketplace get in front of searchers who spend  percent more than the average internet searcher powerful network powerful benefits reach across devicesconnect with customers looking for your business anytime anywhere on any device go global or localreach people in the bing network everywhere or focus on cities counties and areas within a certain distance from your business easy to importif youre already using another product like google adwords its easy to pull that campaign into bing ads you control your costs  free signupjoin bing ads for free and control your account at every step  only pay for clickspay just when customers click on your ad no click no charge  no minimum feestart advertising with a budget that works best for your business   the advantage we gain in cost per click gives us a great return on investment — more than  percent better than google adwords scott redgate search engine marketing manager — cj pony parts by using bing ads features like image extensions and sitelink extensions this auto parts retailer races to convert customers and beat its competition  read about driving more conversions   we might not get as much of the volume as with google adwords but the volume of the traffic that we get converts really well at a lower cost scott schult executive vice president of marketing — myrtle beach area convention and visitors bureau the myrtle beach area convention and visitors bureau uses bing ads to drive site traffic and tourism at lower cost  read about getting better roi better results for less cost thats as simple as i can make it if i look at the quality of the traffic we get for the dollars we spend on bing ads our roi is fantastic alex littlewood ceo   motoroso motoroso a market network for auto enthusiasts gets better results for less cost and reaches a highvalue audience with bing ads  read about attracting quality traffic   import your adwords campaigns save time by importing your google adwords campaigns into bing ads to get ads live quickly sign in with your microsoft account or create one to get started on bing ads from within the bing ads interface select the import from google adwords option enter your google adwords credentials and select the campaign you want to import preview your ad get found online with search engine marketing make the most of your marketing dollars and drive customers to your business see how bing ads can work for you get started today give us a few details about your business to create a bing ads account and get it up and running   sign up get started with bing ads signing up is always free faq is bing ads right for me is bing ads right for my business all types of businesses find value and success with bing ads whether youre focused on local calls and foot traffic or want to drive traffic to your website from across the country or around the world bing ads has solutions for you i already appear in search results for free why should i pay for advertising your current customers may search for your business by name aiming it easy to find you in search results but customers youve yet to reach are more likely searching for general terms that wouldnt necessarily bring up your business in search results advertising next to relevant bing search results puts your business front and center with interested customers you otherwise might not reach what is the difference between seo and sem which one is right for me search engine optimization seo is adjusting your website to improve your natural ranking in search results you cannot pay to improve your website ranking on bing or yahoo thus we often refer to these results and unpaid or organic search results clicks from seo are free but seo also requires technical expertise and involves some factors over which you have only limited control search engine marketing sem is paid advertising that appears next to or above unpaid or organic search results these paid ads are purchased through bing ads you pay for sem clicks but sem gives you more control over when your website appears on results pages and you decide how much you want to pay and you can measure which ads are working and quickly improve your results you dont have to choose between seo and sem you can do both if my time is limited should i still try bing ads yes call a bing ads specialist at and we’ll set up your first campaign for you for free we’ll give you tips on getting the most out of your ads and set you up for success we’re here to help about bing ads where does my ad appear your ads could appear on the top or to the right of bing yahoo and msn search results and you can choose to target your ads to different geographic regions times or days of the week and even demographics what determines my ad position bing ads is a payperclick ppc advertising system you bid based on how much you are willing to pay per each click on your ad because webpages have a limited number of places to show ads we auction those spaces you are bidding against other advertisers to get your ads into the space you want so if you bid on the keyword shoe you will have to beat the bids of the other advertisers who are also bidding on shoe you determine how much you are willing to bid your ad position is based on several things including how closely your ad and website fit with the terms that are searched relevance how your bid compares to other bids in the bing ads auction how strongly your ad has performed in the past and how often it has been clicked clickthrough rate the stronger you are in these areas the better your chances of winning the top ad position how to use bing ads how can i use bing ads to drive more people to my website here are some tips to get better results review your budget and bid strategy if your ad keeps pausing your budget limit may be set too low competitive bids help your ad stay in a strong position to catch eyes and get more clicks to your website expand your targeting both for location and for devices computer mobile and tablet make sure your ads and website are relevant to the keywords you bid on would someone searching your terms expect to see and ad for your business how can i keep my costs down while your first instinct may be to lower your budget first try lowering your maximum bids yes this could mean fewer customers visit your site but if you increase your quality score and build ads with a strong performance history you may be able to win a good ad position with a lower bid that would lower your costperclick and help stretch your budget how do i know if bing ads is working view a wide range of performance trends in your account to quickly see key stats ad clicks the number of times your ad appeared impressions spend average costperclick clickthrough rate average ad position cost per acquisition and conversions you can also run performance reports to get insights into how well your campaigns are doing can i run more than one ad yes in fact we encourage it only one ad will show at a time but running multiple ads lets you test different approaches to see whats working best with your target customers frequently businesses try out different ads for specific products or pages getting started with bing ads how do i get started sign up for bing ads which keywords should i choose you have a few options to help choose your keywords first youll want to think of the terms one of your customers might use to search for your products and offerings those search terms are a great starting point then you can use tools right in your account to find more keywords within bing ads click campaigns on the top of the page click the keywords tab and then click add keywords this will let you search for new keywords based on one you enter search a website for keywords search your destination urls for keywords how can i write a good ad here are a few tips that can help make your ad stand out keep your ads relevant one way to improve relevance is to use your customers most popular search terms in your ad titles and txt describe what sets your product apart use your customers language use words and writing tone that are likely to attract your typical customer be specific this clearer and more specific your offering the better for example rather than big discount specify and exact percentage such as  percent off give customers a reason to click your ad right now offer a specific call to action such as encouraging customers to request a brochure or consultation download a free ebook subscribe to a newsletter or take advantage of a limitedtime discount sign up with bing ads to get started